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AIM OF THE STUDY 
Hematopoiesis is the orderly process of the generation of mature blood cells from few 
committed progenitor cells, which in turn arise from a rare subset of hematopoietic stem cells. 
This process is governed by the interplay of a number of transcription factors that facilitate 
hematopoietic development and influence lineage commitment decisions. Several 
transcription factors of the homeobox and non-homeobox gene family, which are important in 
embryogenesis, are known to play a major role in hematopoietic development. HOX genes are 
highly expressed in early hematopoietic stem cell and in progenitor cells and down-regulated 
during differentiation. In parallel, HOX genes are implicated directly in leukemia, at the level 
of Hox-cofactors (Meis1 and PBX1) and HOX gene upstream regulators. Constitutive 
expression of HOXB4 in human hematopoietic cells leads to an amplification of normal HSC. 
By knocking down the endogenous expression of PBX1 in HOXB4 overexpressing cells, HSC 
are 20 times more competitive in repopulating assays than these overexpressing HOXB4 and 
PBX1. These findings underline the significant role of PBX1 together with HOX genes for 
normal HSC development and for leukemogenesis. Therefore, genes that might interact with 
PBX1 are of particular interest for normal and as well for leukemic hematopoiesis. 
Aim of the study was to define novel regulatory proteins of early human 
hematopoiesis. We first investigated the potential role of a novel human hematopoietic protein 
that interacts with the non-homeobox protein PBX1 (HPIP) in early hematopoiesis. In 
addition, we studied the impact of a novel ventralizing homeobox protein, the Human Vent-
like Homeobox gene (VENTX2) on normal human hematopoietic development. We extended 
our analyses by determining the expression of both proteins in leukemic hematopoiesis by 
analyzing patient samples with different subtypes of acute myeloid leukemia (AML). As 
AML derives from a malignant stem cell we furthermore tested the efficacy of a new specific 
kinase inhibitor SU5614 on normal and leukemic stem cells from patients with AML, 
carrying an internal tandem duplications (ITD) or point mutation (D835) in the tyrosine 
kinase receptor FLT3. 
1. Introduction 
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1. INTRODUCTION 
1.1. Hematopoiesis 
Hematopoiesis is a process that involves the complex regulation of proliferation and 
differentiation of distinct blood cells to the functional components of the bone marrow and 
peripheral blood, including the erythroid, myeloid, lymphoid and platelet lineages that are 
produced from pluripotent hematopoietic stem cells (HSCs) 1 (Figure 1.1). In hematopoiesis 
the ancestral stem cell drives the production of a hierarchy of downstream cells comprised of 
multilineage and unilineage progenitors. This cascade is followed by increasingly mature cells 
more restricted in differentiation capacity, and eventually terminating with the production of 
fully differentiated functional blood cells. The key property that distinguishes pluripotent 
hematopoietic stem cells, from the immediate downstream progenitors which are also 
pluripotent, is their ability to self-renew. This means, that HSC have the potential to generate 
daughter cells with the exact stem cell properties of the parental cells. Normal hematopoietic 
development is noted for the delicate balance between self-renewal and differentiation. When 
the processes of self-renewal and differentiation become deregulated or uncoupled, despite 
the genetic control mechanism that are regulating hematopoiesis, mutation of crucial 
regulatory genes or a perturbation of the normal differentiation program with maturation 
arrest can occur. This can disrupt normal hematopoiesis and promote leukemogenesis, 
characterized by an accumulation of immature blast cells that fail to differentiate into 
functional cells 1. Hematopoiesis, active throughout the human life, is a process involving 
extensive proliferation and differentiation of progenitor cells. These stem cells possess three 
important capacities: self renewal, proliferation and differentiation. The hematopoietic 
hierarchy can therefore be viewed as comprising three compartments stem cells, committed 
progenitor cells and proliferating cells of recognizable morphology each of greater size than 
the preceding (Figure 1.1). This intricate process takes place in a specialized hematopoietic 
microenvironment, which is localized in the bone marrow in the adult 2. This hematopoietic 
microenvironment is of great importance in the maintenance of normal hematopoiesis 3. 
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Figure 1.1. Development of hematopoietic stem cells. HSCs can be subdivided into long-
term self renewing HSCs, short-term self renewing HSCs and multipotent progenitors (red arrows 
indicate selfrenewal). They give rise to common lymphoid progenitors (CLPs; the precursors of all 
lymphoid cells) and common myeloid progenitors (CMPs; the precursors of all myeloid cells). Both 
CMPs/GMPs (granulocyte macrophage precursors) and CLPs can give rise to all known mouse 
dendritic cells. MEP = macrophage erythroid progenitors; MkP = megakaryocyte precursor; ErP = 
erythrocyte precursor; NK = natural killer 4. 
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1.1.1. Hematopoietic Stem Cells 
The existence of a pluripotential hematopoietic stem cell was first demonstrated in 
mice 5. Mouse bone marrow cells injected into lethally irradiated syngenic mice were capable 
of forming discrete nodules in the spleens of the recipients 7 - 14 days after intravenous 
injection. These nodules consisted of erythroid, granulocytic, megakaryocytic and 
undifferentiated colonies and were later found to be derived from single cells called colony 
forming units spleen (CFU-S) 6. The self renewal capacity of primary spleen colony cells 
could be confirmed by the generation of secondary spleen colonies. The equivalence of the 
mouse CFU-S cannot be demonstrated in humans but the presence of a similar pluripotent 
stem cell can be inferred from observations in clonal neoplastic transformations involving 
stem cells. In chronic myeloid leukemia, presence of the Philadephia chromosome can be 
shown in erythroid, granulocytic and megakaryocytic precursors. Isoenzyme analysis in 
patients heterozygous for the enzyme G6PD showed only one isoenzyme in cells of the above 
three lineages. These lines of evidence suggest that pluripotential hematopoietic stem cells 
exist in humans. Stem cells are normally not in active cycle and probably only a small 
proportion is involved in self-renewal. They cannot be morphologically identified and 
probably have the appearance of small lymphocytes. The progenies of stem cells may either 
self-renew or undergo a process called commitment and enter the progenitor cell 
compartment. 
1.1.2. Hematopoietic progenitor cells 
When a stem cell progeny undergoes commitment and therefore becomes a progenitor 
cell, it loses its ability to self-renew and is irreversibly committed to a single lineage of 
hematopoietic differentiation. Studies on progenitor cells became feasible by the development 
of clonogenic assays in semisolid culture media 7. Briefly, in the presence of specific growth 
factors, called colony stimulating factors (CSF), these cells can be clonally cultured in agar or 
methylcellulose as discrete colonies (defined as aggregates of 50 or more cells). Analysis of 
cells of each colony confirmed their clonal nature 8. Progenitor cells are therefore called 
colony forming units (CFU) or Colony-Forming Cells (CFC) and named after the types of 
colonies which they produce in culture (Table 1.1).  
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These progenitors do not have distinguished morphology and are probably blasts in 
appearance. Physiologically, they are in active cell cycle. Each is theoretically capable of 
proliferation and production of all differentiated cells of that particular hematopoietic lineage. 
Progenitor cells are more numerous than stem cells and represent the first amplification step 
in the formation of mature blood cells. Their proliferation is critically dependent on the 
presence of colony stimulating factors (CSF) and can be modified by other lymphokines and 
cellular products. 
 
Colonies Progenitor Cell 
    
Granulocyte G-CFU 
Macrophage M-CFU 
Granulocyte/Macrophage GM-CFU  
Erythroid E-BFU, E-CFU 
Megakaryocyte Meg-CFU 
Eosinophil Eo-CFU- 
Granulocyte,Macrophage, 
Erythroid, Megakaryocyte GEMM-CFU 
Mast cell Mast-CFU 
Fibroblasts F-CFU 
 
Table 1.1. Progenitor cells and their corresponding colonies. Colony forming unit (CFC) 
granulocyte (G), macrophage (M), erythroid (E), megakaryocyte granulocyte (GM), granulocyte, 
macrophage, erythroid, megakaryocyte (GEMM). 
1.2. Role of HOX and non-hox homeobox genes in hematopoiesis 
Homeobox genes are a family of genes involved in regulatory development. These 
genes encode nuclear homeoproteins that act as transcription factors which play important 
roles in development as has been extensively documented in the fruit fly Drosophila 
melanogaster 9,10. These proteins contain a highly conserved common 60-63 residues DNA-
binding homeodomain (HD) that is capable of binding DNA as a monomer 11. Although the 
homeobox genes were initially described as crucial for the correct anterior posterior 
patterning of the embryo in Drosophila and Caenorhabditis elegans as for vertebrates 12. The 
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homeobox was subsequently been identified in a wide range of namly 100 mammalian 
proteins Stein et al. (1996) 
1.2.1. Role of HOX genes in normal and leukemic hematopoiesis 
HD encoding (homeobox-HB) genes are broadly divided into two classes. Class I 
includes clustered HB (HOX) genes, recognized for their role in anterioposterior patterning 
during embryogenesis, while the class II divergent HB (non-HOX) genes are dispersed 
throughout the genome. The HOX gene loci are believed to have arisen from gene duplication 
and consist of 13 paralogous groups organized into four clusters (A-D) on chromosomes 2, 7, 
12 and 17, respectively. During embryonic development genes of the paralogous groups 1 to 
13 are sequentially expressed 3′ to 5′ along the anteroposterior axis and are regulated in a 
temporal and spatial manner. HOX gene expression has been identified in normal 
hematopoietic tissues, including primary human CD34+ stem/progenitor cells, and in 
leukemic samples 13,14. Only expression of HOX genes from paralogous groups A, B and C 
has been detected in normal hematopoietic cells, while expression from all clusters has been 
demonstrated in leukemic cells. Expression of HOXD genes has been shown in a small 
number of leukemic cells, including HOXD3 in the HEL erythroleukemic cell line 15 and 
HOXD13, which is fused to NUP98 in AML 16,17. Several studies imply that HOX proteins 
play a direct role in normal differentiation of hematopoietic cells, with some specificity in the 
lineages that they influence, and that leukemia may arise due to overexpression or perhaps 
absence of HD transcription factors 2. The function of HOX genes in hematopoiesis has been 
investigated through knockout mouse models and enforced overexpression from retroviral 
vectors in hematopoietic stem cells from murine fetal liver and bone marrow and in human 
cord blood progenitors 2. 
1.2.2. Non-HOX homeobox genes in normal and leukemic hematopoiesis 
Homeobox genes are broadly classified into two subclasses: HOX and non-HOX 
homeobox (HB) genes. In contrast to the HOX family, the non-HOX family members are 
intermediate in size and contain five to nine members. Non-HOX HB genes like HOX11 and 
members of the CDX, HLX and PMX1 family are more restricted in their expression patterns. 
They are involved in organogenesis or differentiation of specific cell types. Deregulated 
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expression of non-HOX genes have been implicated in leukemogenesis. Ectopic expression of 
Cdx2 and Hox11 in murine bone marrow results in leukemia 18,19. 
Several non-HOX HD proteins have been shown to function as cofactors for HOX 
proteins and are co-synthesized during embryonic development. These include the three-
amino-acid-loop-extension (TALE) protein, PBX, MEIS and PREP1/KNOX1. They can be 
distinguished from other HD proteins by the inclusion of an additional three amino acid 
within the HD 2. Overexpression of MEIS1 was reported in 50 % of AML patients. Evidence 
from mouse models and human leukemic cells has indicated that inappropriate expression of 
TALE cofactors with certain HD proteins may contribute to leukemic transformation, while 
overexpression of TALE cofactors alone does not lead to disease development. The PBX1 
gene was originally identified at the breakpoint of the t(1;19) translocation found in 10 to 20 
% of childhood pre-B-cell ALL 20. PBX genes are widely expressed in fetal and adult tissues, 
although PBX1 transcripts are notably absent from lymphocytes 21. Comparable to Meis1, the 
cofactor PBX1 enhanced the transforming capacity of the Hox genes Hoxb3 and Hoxb4 
significantly in the transforming assay using RAT1 cells.  
1.2.3. The homeodomain protein family PBX 
PBX1 is a homeodomain protein that functions in complexes with other 
homeodomain-containing proteins to regulate gene expression during development and/or 
differentiation processes. PBX is a member of the PBC protein family. The human PBX1 
protein was initially identified as the chromosome 1 participant of the t(1;19) translocation, 
which occurs in 25 % of pediatric pre-B cell acute lymphocytic leukemia which creates a 
chimeric gene designated E2A-PBX1 22. The mechanism by which E2A-PBX1 causes 
leukemia is still unclear. However, the structure of the fusion protein, in which the majority of 
PBX1, including the homeodomain, is fused to the transcriptional activation domain of E2A 
23,24 suggests that the oncogenic properties of E2A-PBX1 result from inappropriate regulation 
of target genes, of which the expression during hematopoiesis is normally regulated by wild-
type PBX proteins 25,26. In vitro and in vivo data strongly suggest that PBX functions in 
combination with heterologous homeodomain proteins, including class I HOX proteins. As 
HOX cofactors, PBC proteins improve HOX specificity due to the increased size of the 
cooperative binding site and the strength of DNA binding sites by different groups of HOX 
proteins 27,28. In addition, cooperative DNA binding with PBC proteins may act to change the 
regulatory signal of HOX proteins, from repressors to activators 29. PBX proteins appear to 
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function as part of large nucleoprotein complexes. The interactions within these complexes 
are probably decisive factors that allow the DNA binding proteins to discriminate among 
target regulatory elements. How these complexes are regulated during either early embryonic 
development or cellular differentiation of somatic cells to control gene expression is still 
unclear. Abramovich et al. (2000) speculated that the characterization of additional PBX-
interacting proteins might shed light on the mechanism of PBX function, and specifically 
sought to identify novel cofactors or modifiers of PBX1 30. Although the PBX homeodomain 
protein is thought to function as a transcription factor, its mechanism of action is still 
unknown. 
1.2.4. The novel hematopoietic PBX-interacting protein (HPIP) 
The identification of novel proteins which regulate human stem cells and early 
progenitor cell fate decisions is one of the major goals for experimental and clinical 
hematology. Recently, a novel human protein, the hematopoietic PBX-interacting protein 
(HPIP) that interacts with the homeobox gene and HOX co-factor PBX1 was identified 30. The 
new hematopoietic PBX-interacting protein (HPIP) was identified by a yeast two-hybrid 
screen of a fetal-liver hematopoietic cDNA library using PBX1 as bait. HPIP cDNA encodes 
a novel protein of 731 amino acid residues containing no homology to any known protein 30, 
and has a calculated molecular mass of 80 kDa. HPIP is predicted to have a coiled-coil 
domain, suggesting that it interacts with other proteins. HPIP can bind to different members 
of the mammalian PBX family, inhibit the binding of PBX1/HOX complex to DNA and block 
the transcriptional activity of E2A-PBX1, an oncogene found in 25 % of pediatric pre-B cell 
acute lymphocytic leukemia 31. The expression of PBX1 and HPIP was observed by reverse 
transcription-PCR analysis of RNA obtained from bone marrow. HPIP expression was 
detected in CD34+ fraction containing the hematopoietic progenitors and at lower levels in the 
CD34- mature cell population. The same pattern was found for PBX1, indicating that HPIP 
and PBX1 are co-expressed in the same hematopoietic compartment 30. The subcellular 
location shows that HPIP has a complex sub cellular distribution. It is largely bound to the 
cytoskeleton, but has the potential ability to shuttle between the nucleus and the cytoplasm by 
mechanisms involved in nuclear import and export signals 31. 
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1.2.5. The human VENT-like homeobox-2: VENTX2 
The formation of hematopoietic stem cells during development occurs by a multistep 
process that begins with the induction of the ventral mesoderm. This mesoderm is patterned 
during gastrulation by a bone morphogenetic protein (BMP) signaling pathway that is 
mediated at least in part by members of the Mix and Vent families of homeobox transcription 
factors. Following gastrulation, a subset of ventral mesoderm is specified to become 
hematopoietic stem cells 32. Members of the Xvent class of HB genes are essential for the 
patterning of ventral mesoderm and hematopoietic development in the Xenopus laevis embryo 
33. Recently, the mammalian homolog of the Xvent gene was cloned. The HD of this protein 
shares the highest homology with the HD of Xvent2B, which is a direct target of the bone 
morphogenetic protein 4 (BMP4) signaling pathway, making it an interesting candidate for 
involvement in the regulation of hematopoiesis or of hematopoietic stem cell maintenance 34. 
The similarity between the HDs from VENTX2 and the Xvent gene family place them into the 
same class of HD, as they have more than 60 % identity. As a Vent family member Moretti et 
al. (2001) demonstrated that it had ventralizing activity when injected in zebrafish embryos 35. 
In addition, VENTX2 expression was detected in an soybean agglutinin-negative (SBA-) 
population of bone marrow mononuclear cells (BMMNCs), contained 14.2 % CD34+ but not 
in the CD34- subset of BMMNCs that mainly consist of more differentiated hematopoietic 
precursor cells 35. Analysis of a panel of hematopoietic cell lines representative for several 
lineages demonstrated that the VENTX2 protein was present in an erythroid leukemia cell line 
(HEL) and not in several myeloid cell lines35. VENTX2 is the first member of the Vent gene 
family described in mammals. VENTX2 is localized to chromosome 10q 26.3 35. The VENTX2 
protein structure is show in figure 1.2. 
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Figure 1.2. VENTX2 protein structure. VENTX2 encoded 3 exons and a length of 4.03 kb. 
VENTX2 contains a high percentage of serine and threonine residues at the amino terminus, a 
homeodomain (HD) between position 91 and 151, it forms a helix-turn-helix motif which is found in 
many eukaryotic transcription factors and an overall high frequency of proline residues on the carboxy 
terminus. 
1.3. Leukemia 
1.3.1. Acute Myeloid Leukemia 
Acute myeloid leukemia (AML) arises from the clonal expansion of a malignant 
transformed hematopoietic stem cell (HSC) 36,37. This malignancy is characterized by an 
accumulation of a large number of blasts (granulocyte or monocyte precursors) arrested at 
varying stages of differentiation in the blood or bone marrow. These malignant cells gradually 
replace and inhibit the growth and maturation of normal erythroid cells, monocytes and 
megakaryocytes. These deficiencies lead to the hallmark manifestation of this disease, 
namely, weakness, fatigue and pallor as a result of anemia, infection as a result of 
granulocytopenia, and hemorrhage as a result of thrombocytopenia. In addition, in order for a 
leukemic clone to become dominant, it must acquire a significant growth advantage over 
normal cells. Increased cell output could result from increased cell proliferation or from an 
increase in self-renewal potential of leukemogenic stem cells (LSC) with resultant expansion 
of the LSC pool 38.  
 AML belongs to a group of diseases, which have been classified into a number of 
subtypes, based on morphologies and cytochemistry of the AML cells. These subtypes are 
categorized, based on the stage at which normal differentiation is blocked in the leukemic 
blast 39.The most widely-accepted classification is designated by the French-American-British 
(FAB) system (Table 1.2) 40. 
COOHNH2
Homeodomain Proline Rich Region
Pro/Ser/Thr Rich
Region
1 4 88 91 151 258
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Fab 
subtype 
Description Comments 
M0 Undifferentiated Myeloperoxidase negative; myeloid markers positive 
M1 Myeloblastic without 
maturation 
Some evidence of granulocytic differentiation 
M2 Myeloblastic with 
maturation 
Maturation at or beyond the promyelocytic stage of 
differentiation can be divided into those with t(8;21), 
AML1-ETO fusion and those without  
M3 Promyelocytic APL; most cases have t(15;17) PML-RARα or 
another translocation involving RARα 
M4 Myelomonocytic  
M4 Myelomonocytic  
M4Eo Myelomonocytic 
with bone-marrow 
Eosinophilia 
Characterized by inversion of chromosome 16 
involving CBFβ, which normally forms a 
heterodimer with AML1 
M5 Monocytic  
M6 Erythroleukeamia  
M7 Megakaryoblastic GATA1 mutations in those associated with Down's 
syndrome 
 
Table 1.2. French-American-British (FAB) classification of AML. Refers to a 
classification system of acute myeloid leukemia that is based on assessment of the stage of 
differentiation of blast. AML1 = Acute Myeloid Leukemia; APL = Acute promyelocytic Leukemia; 
PML = Promyelocytic Leukemia; RARα retinod-acid receptor-α. Table adapted from Daniel G Tenen 
at al. 40. 
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1.3.2. Epidemiology 
Leukemias comprise 4-5 % of all the cancers among all the age groups. However, 
leukemia in elderly (> 60 years) age group comprises almost one tenth of the total leukemic 
patients. There is a male preponderance (1.4:1). All different types of leukemia are almost 
equal in frequency. The frequency is markedly variable among different age groups, as shown 
in Table 1.3 41,42. AML is seen in all ages, but more than half of the patients with AML are 
aged 60 years or above. 
 
 
Table 1.3. Incidence of Leukemias in different age groups. AML = Acute Myeloid 
Leukemia; CML = Chronic Myeloid Leukemia; CLL: Chronic Lymphoid Leukemia. Table adapted 
from 43. 
1.3.3. Etiology and pathogenesis of acute leukemia  
Acute Myeloid Leukemia (AML), like other cancers, is a progressive clonal disorder 
driven by mutations and is the most frequent leukemia in adults. Pathogenetically, AML 
arises from a malignant transformed clone and is a heterogenic disease, arising from a variety 
of pathophysiological mechanisms. The exact etiology is not known, but radiations, viruses, 
immunological factors, chemicals like benzene and toluene are associated with increased risk 
of leukemias. Despite advances in understanding the pathophysiology and treatment of AML, 
Type of leukemia Age Group (Median age) Incidence per 
100,00/yr. 
Sex ratio (M:F) 
AML <65 years 1.3 2.9:1.9 
 >65 years 12.2  
CML 25-60 years (peak 40-50) 1.3 1.7:1.0 
ALL Children & Young adults  
(80 %) 
1.3  M>F 
 >70 years small rise M>F 
CLL (30 %) <50 1.0  
 >70 10.0  
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the long term survival of patients <65 years old, is about 40 % 44. The reasons for failure of 
therapy are e.g. multidrug resistance and therapy associated morbidity. Patients who have a so 
called myelodysplastic syndrome(MDS) have a high risk of developing AML which 
commonly occurs in the older age group (24 %) 45. Secondary AML following chemotherapy, 
like alkylating reagents or radiotherapy, used for treatment of other malignancies, is also more 
common in older patients. These secondary AMLs are associated with chromosomal 
abnormalities like 5/del (5q) and or 7/del (7q) 45. The cytogenetic analysis of leukemic blasts 
leads to the identification of various chromosomal, disease-specific clonal aberrations. Some 
of these aberrations correlate with morphological subtypes and response to therapy. Thus, 
cytogenetic and molecular analysis is an important part of the initial routine diagnostics and 
for disease monitoring in AML. A variety of other chromosomal abnormalities may occur in 
acute leukemia. Philadelphia chromosome (PH) designated as t(9;22) is present in more than 
95 % of CML patients. There is increased incidence of (PH) chromosome in ALL patients of 
older age group and it is associated with poor prognosis 43. Because of their importance for 
biology and prognosis, leukemia associated cytogenetics are an essential criteria within the 
WHO classification 46. Although, the pathophysiology of AML is not fully understood, 
possible pathogenetic factors are shown in figure 1.3 47. 
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Figure.1.3. Major factors influencing etiology of cancer 47 
1.3.4. Hierarchy of leukemias 
Several studies have shown that the hierarchy inside the hematopoietic compartment is 
maintained following leukemic transformation 48. Some leukemia cells are capable of forming 
colonies in semi-solid media under addition of growth factors (AML colony-forming cells or 
AML-CFC) 49. Additionally, progenitor cells have been found which are detectable in lower 
frequency  than AML-CFC and which can sustain a malignant long-term hematopoiesis in 
stroma cell-dependent co-cultures or in liquid cultures upon addition of growth factors50. The 
immunophenotype of these cells initiated by long-term cultures (AML-LTC-IC) or short term 
cultures (AML-SC-IC) seems to be very similar to the normal LTC-IC 14,50,51. AML-LTC-IC 
cells express CD34 in the absence of CD38 such as the corresponding cells in normal 
hematopoiesis. Therefore, among the leukemia population there are stages of clonogenic 
progenitor cells as well as LTC-IC which both, like the CD34+ CD38- subpopulation, carry 
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leukemia-specific aberrations in the majority of patients 36,52-54. They can also persist in the 
stage of morphologically complete remission 37. Furthermore, using the mouse transplantation 
model with AML patient samples the stages of early re-populating stem cells are detectable. 
These early hematopoietic stem cells which are called competitive repopulating units (CRU) 
usually have the capability to reconstitute multilineage in lethally irradiated mice.  
In the human system the repopulation occurs after sublethal irradiation of immune 
deficient Non-obese/LTSz-scid/scid (NOD/SCID) mice following intravenous injection of 
human bone marrow or cord blood stem cells 55-60. 
In the leukemic population of patients with AML, these early AML inducing leukemic 
stem cells are detectable (so called  AML NOD/SL-IC) and lead to the repopulation of mice, 
but do not yield a multilineage engraftment as seen with the normal CRU. Instead, they 
mostly repopulate the mice  with blast cells similar to AML 59-64. It could be shown that blast 
cells derived from patients with AML with an unfavorable karyotype engraft statistically 
better than blast cells with AML M3 or M2 61. The frequency of NOD/SCID leukemia-
initiating cells (NOD/SL-IC) is variable from patient to patient and with 0.7 - 45 per 107 cells, 
about. 200- to 800-times lower than the frequency of AML-LTC-IC in the same samples. 
Immunophenotypically NOD/SL-IC are characterized by the following surface markers: 
CD34+ CD38- 62,63, CD71- and HLA-DR- 65, Thy-1- 66and c-kit 67. Further on, it could be 
demonstrated that the morphologic/cytogenetic subtype is sustained in these mice. Using the 
NOD/SCID mouse model, it is therefore possible to identify earliest leukemic stem cells, to 
characterize them and to determine their frequency using the limiting dilution analyses 61,68. 
The fact that these models are  equally applicable for the detection and characterization of 
normal stem cells makes the comparative analysis of  normal versus leukemic stem cells 
feasible (Figure 1.4).  
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Figure 1.4. Hierarchy of hematopoiesis.  The figure shows the in vivo and in vitro analyses 
which represent the individual levels of differentiation in the hematopoietic hierarchy. 
1.4. AML-associated mutations 
Cancers are known to arise from mutations or other acquired genetic changes. The 
genetic changes implicated in leukemias are most commonly chromosomal aberrations and 
receptor disregulation. Chromosomal aberrations contribute to a vast majority of cancers and 
the link between the occurrence of chromosomal aberrations and cancer has been very well 
established due to current advances in cytogenetic and molecular biology. Analyses of 
recurring chromosomal aberrations have led to the identification of numerous proto-
oncogenes 69. More than 80 % of myeloid leukemias are associated with at least one 
chromosomal rearrangement 70 and over 100 different chromosomal translocations have been 
cloned so far 71. A few of the frequent chromosomal rearrangements are described below 
followed by a brief description of receptor internalization in AML (Table 1.4) 40. 
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Table 1.4. Medical Research Council (MCR) classification of AML. AML = acute myeloid 
leukemia; C/EBPα, CCAAT/enhancer binding protein-α; ITD = internal tandem duplication 40. 
1.4.1. Translocation t(8;21) 
A common chromosomal translocation in acute myeloid leukemia (AML) involves the 
AML1 (acute myeloid leukemia 1, also called RUNX1, core binding factor protein (CBFa), 
and PEBP2aB) gene on chromosome 21 and the ETO (eight-twenty one, also called MTG8) 
gene on chromosome 8. This translocation generates an AML1-ETO fusion protein. AML1-
ETO is a multifunctional protein exemplified by its role in regulating diverse cellular 
programs such as differentiation, proliferation, apoptosis, and self-renewal in various in vitro 
and in vivo models. It regulates the expression of both AML1 target and non-AML1 target 
genes via its interaction with various transcription regulators. Furthermore, additional 
mutations besides t(8;21) are necessary for the development of AML. t(8;21) is associated 
with 12 % of de novo AML cases and up to 40 % in the AML subtype M2 of the French–
American-British classification. Moreover, it is also reported in a small portion of M0, M1, 
and M4 AML samples. Despite numerous studies on the function of AML1-ETO, the precise 
mechanism by which the fusion protein is involved in leukemia development is still not fully 
understood 72. 
1.4.2. Inversion 16 inv(16) (p13;q22) 
The inv(16) (p13;q22) translocation is found in more than 90 % of patients with AML 
M4Eo subtype, which has distinctive morphological abnormalities in the bone marrow 
Subtype Medical Research Council MCR MCR and mutation status 
Favorable 
 
t(15;17, Inv(16), t(8;21) t(15;17), Inv(16), t(8;21) or C/EBPα 
mutation without FLT3 ITD or 
adverse cytogenetics 
Intermediate 
 
All others C/EBPα mutation with FLT3 ITD or 
all others  
Unfavourable 
 
Del(5q)/-5, -7, 3q; complex 
karyotypic abnormalities 
Del(5q)/-5, -7, 3q; complex 
karyotypic abnormalities 
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including myelomonocytic differentiation and an increase in atypical bone marrow 
eosinophils. The result of the fusion of the core-binding factor beta (CBFβ) gene and the 
myosin heavy polypeptide 1 (MYH11) gene is the inv(16)(p13;q22) and is thought to be a 
necessary genetic lesion in this form of leukemia. The most common fusion point occurs at 
CBFβ nucleotide (nt) 495 and MYH11 (nt) 1921; however, several rare variants have been 
described 73. 
1.4.3. Translocation 11q23 
Rearrangements of the MLL gene (also termed ALL1 or HRX) located at chromosome 
band 11q23 are commonly involved in adult and pediatric cases of primary acute leukemias 
and also found in cases of therapy-related secondary leukemias. These translocations lead to 
fusion genes generally resulting in novel chimeric proteins containing the amino terminus of 
MLL fused in-frame to one of about 30 distinct partner proteins. Abnormalities involving the 
MLL gene are observed in leukemias of either lymphoid or myeloid lineage derivation, as 
well as in poorly differentiated or biphenotypic leukemias. They are frequently seen in infant 
patients and patients with therapy-related secondary AML following treatment with inhibitors 
of topoisomerase II (epipodophyllotoxins). In the majority of cases, abnormalities involving 
the MLL gene are associated with a very poor prognostic outcome. 
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1.5. Signal transduction 
Signal transduction pathways provide a mechanism for intracellular signals. Binding 
of ligands, such as e.g. G-CSF, GM-CSF or FLT3 ligand to their receptors causes intracellular 
reactions as proliferation, differentiation or apoptosis. As an example a simplified cartoon of 
the FLT3 signaling net work is shown in Figure 1.5.  
 
 
 
Figure 1.4. The FLT3 signaling cascade 1 Explanation see text 
 
Although the FMS-like tyrosine kinase 3 (FLT3) signaling cascade has not been 
definitively characterized, this figure shows some of the complex associations and 
downstream effects that probably occur after activation of FLT3. Binding of FLT3 ligand (L) 
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to FLT3 triggers the PI3K (phosphatidylinositol 3-kinase) and RAS pathways, leading to 
increased cell proliferation and the inhibition of apoptosis. PI3K activity is probably regulated 
through various interactions between FLT3, SH2-containing sequence proteins (SHCs) and 
one or more other proteins, such as SH2-domain-containing inositol phosphatase (SHIP), 
SH2-domain-containing protein tyrosine phosphatase 2 (SHP2), CBL (a proto-oncogene) and 
GRB2-binding protein (GAB2). Activated PI3K stimulates downstream proteins such as 3-
phosphoinositide-dependent protein kinase 1 (PDK1), protein kinase B (PKB/AKT) and the 
mammalian target of rapamycin (mTOR), which initiate the transcription and translation of 
crucial regulatory genes through the activation of p70 S6 kinase (S6K) and the inhibition of 
eukaryotic initiation factor 4E-binding protein (4E-BP1). In addition, PI3K activation blocks 
apoptosis through phosphorylation of the pro-apoptotic BCL2-family protein BAD (BCL2 
antagonist of cell death). Activated FLT3 also associates with GRB2 through SHC, so 
activating RAS. RAS activation stimulates downstream effectors such as RAF, MAPK/ERK 
kinases (MEKs), extracellular-signal-regulated kinase (ERK), and the 90-kDa ribosomal 
protein S6 kinase (RSK). These downstream effectors activate cyclic adenosine 
monophosphate-response element binding protein (CREB), ELK and signal transducer and 
activators of transcription (STATs), which lead to the transcription of genes involved in 
proliferation. Both pathways probably also interact with many other antiapoptotic and cell-
cycle proteins, such as WAF1, KIP1 and BRCA1. Solid arrows depict direct associations 
between proteins, whereas dashed arrows depict associations that have been indicated 
indirectly 1. 
1.5.1. Overview of normal RTK/RAS/MAP kinase pathway  
Tyrosine kinases help to regulate cell growth, division and differentiation 74. These 
proteins are generally divided into two major classes: proteins related to SRC proto-oncogene 
and transmembrane receptor tyrosine kinases (RTKs). Sub-class III RTXs (PDGFRA, 
PDGFRB, FMS, KIT and FLT3) are characterized by an extracellular ligand-binding region 
consisting of five immunoglobulin-like domains, a transmembrane and juxtamembrane (JM) 
and an intracellular domain with kinase activity RTXs are normally activated by receptor-
specific ligand (L), which bind to the extracellular domains and promote phosphorylation of 
the intracellular tyrosine kinase domains (Figure 1.5) 75,76. 
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1.5.2. Receptor downregulation 
Receptor downregulation is an important mechanism that regulates cell signaling by 
causing the internalization and degradation of the ligand or the entire ligand-receptor 
complex. Receptors that are defective for down regulation are oncogenic, furthermore, 
receptor overexpression is one of the most consistent features of cancerous cells. 
Overexpression of M-CSF and FMS is causally implicated in the development of the majority 
of uterine, ovarian and breast cancers. Down regulation of FMS is initiated by movement of 
the activation segment of the kinase domain as a result of ligand binding 77,78. 
1.5.3. Abnormal signal transduction 
Abnormalities, including mutations, aberrant expression and inappropriate 
methylation in genes that are involved in signal transduction pathways are common in AML. 
The precise cellular consequences of these genetic abnormalities are unknown, but 
functionally, these abnormalities probably promote proliferation, abate differentiation, and/or 
prevent apoptosis. Mutations in the FLT3 gene are some of the most common events in AML 
79. 
1.6. Expression of FLT3 in normal and leukemic cells  
Despite the many genetic checks and balances to regulate hematopoiesis, in place, 
mutations of crucial regulatory genes that disrupt normal hematopoiesis and promote 
leukemogenesis can occur. Receptor tyrosine kinases are a subclass of cell-surface growth-
factor receptors with an intrinsic, ligand-controlled tyrosine-kinase activity. They regulate 
diverse functions in normal cells and have a crucial role in oncogenesis. The FMS-like 
tyrosine kinase 3 (FLT3) genes encodes a membrane-bound receptor tyrosine kinase (RTK) 
that has an important role in the normal development of stem cells and the immune system. 
FLT3 is expressed in a variety of human and murine cell lines of both myeloid and B-
lymphoid lineage 80,81. In normal human bone marrow cells, expression of FLT3 appears to be 
restricted to early myeloid and lymphoid progenitors 82, including CD34+ cells with high 
levels of CD117 (c-KIT) 82,83. FLT3 is not expressed in erythroid cells 84, megakaryocyte 85 or 
mast cells 86 (Figure 1.6). Many types of leukemic cells express FLT3. In most types, FLT3 
expression by the leukemic cell mirrors the expression of the normal cell counterpart (Figure 
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1.6). So, FLT3 is expressed by myeloid and lymphoid progenitors, and by leukemic cells of 
70 to 100 % of patients with acute myeloid leukemia (AML) 85,87. FLT3 is expressed in all 
FAB subtypes, which originate from primitive, multipotent colony-forming cells or myeloid-
committed colony-forming unit cells 88 and in ALL deriving from immature, progenitor B 
cells 89. B-cell chronic lymphocytic leukemia (CLL) cells do not express FLT3 arising from a 
more mature lymphocytic population 90. 
 
 
 
Figure 1.5. Expression of FLT3 in normal hematopoiesis. The maturation and 
differentiation of cells during normal hematopoiesis is shown, indicating how expression of FMS-like 
tyrosine kinase 3 (FLT3) is linked to this process (shown as +, –, +/– or ? (unknown)). FLT3 is mainly 
expressed by early myeloid and lymphoid progenitor cells, with some expression by the more mature 
monocytic lineage cells. Colony-forming units for the erythroid (E-CFU), megakaryocytic (MK-CFU), 
granulocytic–monocytic (GM-CFU), basophilic (B-CFU), granulocytic (G-CFU), monocytic (M-
CFU), and dendritic (D-CFU) lineages are shown. NK cell, natural killer cell; RBC, red blood cell 1.  
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1.6.1. Structure of the FLT3 receptor 
FLT3 (Fms-like tyrosine kinase 3), also known as FLK-2 (fetal liver kinase-2) and 
STK-1 (human stem cell kinase-1) 91 was cloned independently by two groups in 1991 92. The 
human FLT3 gene is located on chromosome 13q12, shows an 85 % amino-acid sequence 
homology to the mouse Flt3 protein. FLT3 encodes a receptor tyrosine kinase (RTK) of 993 
amino acids in length 91,93. The FLT3 receptor has the same general structure as four other 
tyrosine kinase receptors that comprise the type III RTK subfamily: c-FMS, the receptor for 
colony stimulating factor-1 (CSF-1), c-KIT, and both of the receptors for platelet-derived 
growth factor (PDGFRα and PDGFRβ). Each of these receptor molecules are characterized 
by membrane-bound receptors with five immunoglobulin-like extracellular domains, a 
transmembrane domain, a juxtamembrane domain and two intracellular tyrosine kinase 
domains (TDKs) linked by a kinase insert domain 1 (Figure 1.6).  
 
 
 
Figure 1.6. Processing, ligand-binding and internalization of FLT3. All members of the 
RTK subclass III family play an important role in proliferation, differentiation and survival of normal 
hematopoietic cells 1. 
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1.6.2. FLT3 mutations in hematopoietic malignancies 
The first “complementation group” of mutant genes in AML confers proliferative 
and/or survival advantage to hematopoietic progenitors, usually as a consequence of aberrant 
activation of signal transduction pathways. Nakao et al (1996) first described FLT3 mutations 
in hematopoietic malignancies which stimulated a lot of research 94, characterizing the 
frequency and relevance of FLT3 mutations 94,95. The most common form of FLT3 mutation is 
the internal tandem duplication (ITD) in exon 14 and 15 (previously known as exon 11 and 
12) which occurs in 15-35 % of patients with AML 94,96,97 and 5-10 % of patients with 
myelodysplasia 95,98. ITDs are formed when a fragment of the juxtamembrane-domain coding 
sequence is duplicated and insert in a direct head-to-tail orientation. The consequence of the 
ITD mutations is the constitutive activation of FLT3 tyrosine kinase activity. The length 
mutation of the ITD varies from 3 to ≥ 400 base pairs, and the reading frame of the transcript 
is always preserved, either by a faithful in frame duplication or by insertion of nucleotides at 
the ITD junction to maintain the original reading frame 99.  
The second most common type of FLT3 mutation is a mis-sense point mutation in 
exon 20 (previously known as exon 17) of the tyrosine kinase domain (TKD). TKD mutations 
occur in patients with AML (5-10 %), MDS (2-5 %) and ALL (1-3 %) 100-102, and the most 
frequent nucleotide substitution (GAT-->TAT) changes an aspartic acid to tyrosine (D835Y). 
Other mutations in codon 835, such as deletions, have also been described, but these are far 
less common. In addition, point mutations, deletions and insertions in the codons surrounding 
codon 835 have also been found 101,103,104. Similar to the ITDs, all TDK mutations maintain 
the same open reading frame (Figure 1.7). 
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Figure 1.7. Structure and location of FLT3 mutations. A | Internal tandem duplications 
(ITDs) occur in exons 14 or 15 of the juxtamembrane domain (JM), which lies directly between the 
transmembrane domain (TM) and the first tyrosine-kinase domain (K1). Point mutations (PM), 
insertions and deletions are found in exon 20 of K2 1. 
 
1.6.3. Biology of ITD mutations 
In vitro transduction studies have shown that ITDs promote ligand-independent 
dimerization, autophosphorylation and constitutive activation of the receptor 105-107. How 
ITDs promote constitutive activation is unknown. Experimental data indicate that mutations 
in the juxtamembrane domain probably eliminate the naturally occurring repressive regions of 
FLT3, which normally prevent dimerization without ligand stimulation. Various mutations 
(insertions, deletions or duplications) in several regions of the juxtamembrane domain cause 
constitutive activation of the receptor. In addition, FLT3 engineered with an ITD, but not with 
a TDK region, dimerizes with wild-type receptor without the addition of ligand and can 
activate wild-type FLT3 108. The constitutive activation induced by ITDs promotes ligand-
independent proliferation and blocks myeloid differentiation of early hematopoietic cells in a 
mouse model system 109. Recently, Kelly et al. (2000) found that ITDs induce a 
myeloproliferative-like disease in mouse bone marrow transplant models 110. These 
experiments indicate that ITDs are sufficient to promote phenotypical changes associated with 
enhanced proliferation. But they are not sufficient to induce acute leukemia. 
1.6.4. Biology of TDK point mutations 
Mutations in the TDK region of FLT3 also promote constitutive phosphorylation of 
the receptor and ligand-independent cell growth 102,103. It is not known how TDK mutations 
activate the receptor or whether the activation of TDK-mutant FLT3 more closely resembles 
that of wild-type FLT3 or of ITD. There is ~ 80 % identity between the TDKs of FMS, KIT 
and FLT3 75, and TDK mutations have been found ion both FMS and KIT 111,112. In TDK- 
mutated FMS and KIT, the tyrosine kinase activity is highly dependent on the type of amino-
acid substitution in the TDK, such that some point mutations cause a marked increase in 
activity, whereas others inhibit activity 113,114. These experiments are in sharp contrast to the 
mutational experiment with the juxtamembrane domain of FLT3, which shows that any 
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mutation in the juxtamembrane region causes an increase in activity 108. On the basis of 
experimental data with other RTK subclass III receptors, TDK mutations probably increase 
the level of intrinsic tyrosine-kinase activity, rather than interfering with repressive domains 
and promoting dimerization 1. 
1.7. Clinical relevance of ITD mutation 
FLT3 mutations are of clinical importance 94,96,98,115-117. ITDs have been strongly 
associated with leukocytosis, high blast count, normal cytogenetic, and the translocations 
t(15;17) and t(6;9). Recently, one study indicated that ITDs might also be associated with 
duplications and/or double strand DNA breaks in the breakpoint cluster of the MLL gene 118. 
The prevalence of ITDs in patients with AML increases with age, ranging from 5-15 % in 
pediatric patients to 25-35 % in adults. Most studies in pediatric patients with AML have 
found that ITDs are strong, independent predictors of poor clinical outcome 116,117,119. Studies 
in adult patients with AML are not as conclusive, but still show an overall trend for poor 
clinical outcome in patients with ITDs 96,99,120.. Despite attempts to stratify patients with AML 
according to risk factors on the basis of their presenting clinical and laboratory characteristics, 
outcomes after chemotherapy for similar patients are highly variable. Perhaps not all ITDs are 
equal, although there are no data to support this hypothesis. Other possibilities are that other 
genetic abnormalities associated with ITDs confound the analyses, by making the outcome 
either worse or better. 
ITDs have been associated with other known prognostic abnormalities such as 
t(15;17), t(6;9) and MLL mutations 101,118. Some of these genetic abnormalities, such as 
t(15;17), are associated with a good prognosis, whereas others, such as t(6;9), are associated 
with poor clinical outcome 121. Knowledge of how ITDs that interact with other cytogenetic 
abnormalities might provide a biological insight into leukemogenesis and clarify the 
uncertainties of risk stratification. 
Two studies of patients with AML with t(15;17) found no significant impact of ITDs 
on clinical outcome, but there was a trend (not statistically significant) towards shorter 
disease-free survival and higher relapse rates in patients with a FLT3 mutation 122,123. In 
addition, both studies found a significant association between ITDs and leukocytosis, which 
indicates that the ITD has a proliferative biological effect in cases of AML with t(15;17). 
ITDs are mainly found in heterozygous state, but sometimes they are found in a single-copy, 
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homozygous state after loss of the normal FLT3 allele. Some sub-populations of AML cells 
might have an ITD, whereas others contain only wild-type FLT3. For example, FLT3 
mutational status can change between diagnosis and relapse, with some patients developing a 
new or different FLT3 mutation on relapse, whereas other patients lose their FLT3 mutation 
completely 123,124. If leukemia contained two clones with different FLT3 mutation status (one 
with cells containing an ITD and one with wild-type FLT3), then patients with a higher 
percentage of clones with ITDs would have higher ITD wild-type ratios. If the cells with the 
ITD are more resistant to therapy, then patients with higher ITD wild-type ratios would have 
more likely a poor clinical outcome than patients having a lower ratio. It is not known how a 
high ITD: wild-type allelic ratio effects mRNA and protein expression of the mutant and 
wild-type alleles. It would be expected that those samples with a high ITD: wild-type allelic 
ratio would also have a higher level of ITD mRNA and of ITD protein expression. Recently, 
Libura et al. (2003) examined the relative mRNA expression of 31 patients with AML 
carrying ITDs compared to 100 patients with AML carrying wild-type FLT3 118. Overall, the 
mean FLT3 mRNA expression of the ITD group was not significantly different from that of 
the wild-type group, but there was a wide range of FLT3 expression within the patients with 
ITD and wild-type FLT3. As noted previously, wild-type FLT3 expression is increased in 
high-risk patients with MLL translocations 125. 
1.8. FLT3 as a target for therapy in AML  
FLT3 is the most commonly mutated gene in AML and confers a poor prognosis in 
most patients. As a consequence, there has been an intensive effort to develop selective 
inhibitors as therapeutic reagents.  
After the success of Imatinib STI571 (Glivec; Novartis), a small-molecule tyrosine 
kinase inhibitor (TKI) used to treat CML 126, there has been a tremendous effort to discover 
other small-molecule inhibitors that could be efficacious for other malignancies. Given the 
high frequency of activating FLT3 mutations in patients with AML, FLT3 and its downstream 
pathway are attractive targets for directed inhibition. Preclinical studies in patients but also 
studies in cell culture and murine models of leukemia mediated by ITD, provide further 
support for this strategy 127,128.  
In a pivotal set of preclinical experiments, STI571 was shown to suppress the 
proliferation of Bcr-Abl–expressing cells in vitro and in vivo. In colony-forming assays of 
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peripheral blood or bone marrow from patients with CML, STI571 caused a 92–98 % 
decrease in the number of Bcr-Abl colonies formed, with minimal inhibition of normal colony 
formation 129. Cellular in vivo and human ex-vivo studies convinced that STI571 could be 
useful in diseases involving deregulated Abl PTK activity. The efficacy and specificity of 
STI571 has been confirmed and extended by several laboratories 130,131. It was demonstrated 
that STI571 has activity against p185 Bcr-Abl and another activated Abl fusion protein, Tel-
Abl 126,130,132.  
Non-specific TKIs such as the tyrphostin A AG1296 and AG1295, block  the 
constitutive activation of ITDs, as well as other proteins such as heat shock protein 90 
(HSP90), thereby inhibiting the growth of cells that express ITDs 133,134. These compounds 
are selective inhibitors of FLT3, KIT, and PDGFR. For example, the tyrphostin AG1296 
inhibits the growth of Ba/F3 cells transformed by ITD and FLT3 autophosphorylation and 
activation of downstream targets such as STAT5A/B 127. A related compound, AG1295, also 
inhibits ITD mutants and has specific toxicity for primary AML blasts harboring ITD 
compared with cytosine arabinoside 135. It has also been reported that Herbimycin A is a 
submicromolar inhibitor of FLT3 and prevents leukemia progression in mice injected with 
32D cells expressing ITD. Although none of these compounds would be suitable for 
consideration in clinical trials in humans, these experiments provide evidence that FLT3 
inhibition may be an effective approach to the subset of leukemias with activating mutations 
in FLT3 and perhaps for AML associated with overexpression of the wild-type FLT3. 
Several promising TKIs have been identified recently that might change the treatment 
of hematopoietic malignancies. CEP-701 and CEP-5214 (Cephalon) are two orally 
bioavailable TKIs derived from indolocarbazole 136,137. Both compounds preferentially inhibit 
autophosphorylation of wild-type and mutant FLT3, and show limited inhibition of KIT, FMS 
and PDGFR. Levis et al. (2002) found that CEP-701 is cytotoxic to leukemia blasts from 
patients with AML in vitro and in vivo, and prolongs the survival of mice injected with 
BaF3/ITD cells 136. A Phase I/II trial is now underway, testing CEP-701 in patients with 
refractory and relapsed AML with FLT3 mutations, and preliminary results have been 
presented in key abstract form at the American Society of Hematology 138. In eight patients, 
CEP-701 seemed to be relatively well tolerated, with nausea, fatigue and neutropaenia being 
the most commonly described side effects. CEP-701 dosage has now been titrated to 80 mg 
twice a day. At this early stage, it is difficult to discern the potential efficacy of CEP-701, but 
one patient did normalize his peripheral-blood counts, with <5 % blasts in his bone marrow, 
which indicates that this agent might be beneficial in some patients with AML. 
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The company Sugen has also identified several compounds (SU5416, SU5614 and 
SU11248) that block FLT3 activation 139,140. Unlike the compounds developed by Cephalon, 
these agents also inhibit other RTKs such as KIT, PDGFR and VEGFR 139,140. After initial 
Phase I trials, Giles et al. recently examined SU5416 at a dose of 145 mg per m2 in 55 
patients with refractory or relapsed AML regardless of FLT3 status 141. The main side effect 
included headaches (14 % of patients), dyspnoea (14 %), infusion-related reactions (11 %) 
and thrombotic episodes (7 %). Three patients (5 %) had a partial response. An early Phase I 
trial examined SU11248 in 32 patients with advanced AML. Again, FLT3 mutations were not 
taken in account in this trial. SU11248 was relatively well tolerated, with fatigue being the 
main dose-limiting toxicity 142. Approximately half of the patients had some form of 
haematological response as shown by a > 50 % reduction in the number of leukemia blasts.  
MLN518 (otherwise known as CT53518 from Millenium) is a novel piperarazinyl 
quinazoline that inhibits the growth of ITD-transformed cells in vitro and in vivo 110. Similar 
to the Sugen compounds, MLN518 also inhibits wild-type FLT3, PDGFRB and KIT. In a 
Phase I study including patients with relapsed or refractory AML, preliminary findings 
showed that two of six patients had < 50 % reduction in the number of bone blast. This study 
is currently in progress with additional patients 143. 
Lastly, PKC412 (Novartis) is a benzoylstaurosporine initially developed as a VEGFR 
inhibitor that blocks the activity of wild-type and mutant FLT3 125,144. On the basis of Phase I 
dosing studies in solid tumors, a Phase II trial started studying PKC412 at a dose of 75 mg 
three times a day in patients with relapsed or refractory AML with FLT3 mutations 145. All 
patients had a poor prognosis for myelosuppressive chemotherapy and had a poor 
performance status. Mild nausea was the most common side-effect in the first eight patients, 
but three of the eight patients discontinued use of the drug for reasons other than progression 
of disease (liver toxicity, fatal pulmonary toxicity and severe lethargy). It is unclear if these 
complications were related to drug administration. No partial or complete responses were 
obtained in this heavily pre-treated and debilitated patient population. Analysis of results is 
continuing, and additional data should be available in the near future. Of additional interest is 
the fact that PKC412 has been found to kill leukemia cells with MLL translocations that 
overexpress wild-type FLT3 125,146. These findings indicate that PKC412 (and possibly other 
TKIs) might be effective for the treatment of a wide range of hematopoietic malignancies that 
overexpress FLT3, even if they do not have activating FLT3 mutations. If similar experiments 
can validate these findings in other  cell lines and primary AML samples, then the therapeutic 
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use of TKIs might broaden to include other malignancies, such as AML and B-cell ALL, or 
any hematopoietic disease that overexpresses FLT3. 
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2. MATERIALS 
2.1. Reagents, cytokines and antibodies 
Reagents Company 
Acetic acid  Sigma-Aldrich, Taufkirchen, Germany 
Agar Sigma-Aldrich, Taufkirchen, Germany 
Agarose Sigma-Aldrich, Taufkirchen, Germany 
BIT Stem Cell Technologies, Vancouver, BC, Canada 
Bromphenolblue  Sigma-Aldrich, Taufkirchen, Germany 
BSA  
Calcium Chloride Sigma-Aldrich, Taufkirchen, Germany 
Ciprobay 400 Bayer 
DMSO Sigma-Aldrich, Taufkirchen, Germany 
DMEM PAN Biotech, Aidenbach, Germany 
Ethanol Sigma-Aldrich, Taufkirchen, Germany 
Ethidium Bromide Sigma-Aldrich, Taufkirchen, Germany 
Fetal Bovine Serum PAN Biotech, Aidenbach, Germany 
Formaldehyde Sigma-Aldrich, Taufkirchen, Germany 
Geneticin GIBCO, Invitrogen Corporation,Karlsruhe,Germany  
HEPES GIBCO, Invitrogen Corporation,Karlsruhe,Germany  
HLTM (Myelocult H5100) Stem Cell Technologies, Vancouver, BC, Canada 
Hydrocortisone (solucortef) Stem Cell Technologies, Vancouver, BC, Canada 
IMDM GIBCO, Invitrogen Corporation,Karlsruhe,Germany  
Isopropanol Sigma-Aldrich, Taufkirchen, Germany 
LDL Stem Cell Technologies, Vancouver, BC, Canada 
L-Glutamine  
Methanol Sigma-Aldrich, Taufkirchen, Germany 
Methilcellulose H4330 Stem Cell Technologies, Vancouver, BC, Canada 
Methilcellulose H4334 Stem Cell Technologies, Vancouver, BC, Canada 
Pancoll PAN Biotech, Aidenbach, Germany 
PBS PAN Biotech, Aidenbach, Germany 
Penicillin/Streptomycin GIBCO, Invitrogen Corporation,Karlsruhe,Germany  
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RPMI PAN Biotech, Aidenbach, Germany 
SDS Sigma-Aldrich, Taufkirchen, Germany 
Sodium Chloride Sigma-Aldrich, Taufkirchen, Germany 
Trypan blue GIBCO, Invitrogen Corporation,Karlsruhe,Germany  
Trypsin/EDTA GIBCO, Invitrogen Corporation,Karlsruhe,Germany  
β- Mercaptoethanol Sigma-Aldrich, Taufkirchen, Germany 
Cytofix (Cell fixation reagent) BD Pharmingen 
 
 
Cytokine  
SF Steel factor ImmunoTools Friesoythe; Germany 
GM-CSF Tebu-bio, Frankfurt, Germany 
G-CSF  Stem Cell Technologies 
Flt-3-ligand PAN Biotech GmbH, Aidenbach, Germany 
IL6 Tebu-bio, Frankfurt, Germany 
IL3 ImmunoTools Friesoythe; Germany 
 
 
 
Antibody Company 
CD45PE BD Pharmingen,Heidelberg, Germany 
CD34 PE BD Pharmingen,Heidelberg, Germany 
CD38 APC BD Pharmingen,Heidelberg, Germany 
CD15PE BD Pharmingen,Heidelberg, Germany 
CD19 APC BD Pharmingen,Heidelberg, Germany 
CD33PE  BD Pharmingen,Heidelberg, Germany 
CD36 APC BD Pharmingen,Heidelberg, Germany 
CD135 PE BD Pharmingen,Heidelberg, Germany 
CD71APC BD Pharmingen,Heidelberg, Germany 
CD41APC BD Pharmingen,Heidelberg, Germany 
CDF123PE BD Pharmingen,Heidelberg, Germany 
CD25APC BD Pharmingen,Heidelberg, Germany 
CD11bPE BD Pharmingen,Heidelberg, Germany 
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CD40APC BD Pharmingen,Heidelberg, Germany 
 
 
Reagent Kits Company 
MACS CD34 Cell Isolation Kit Miltenyi Biotec GmbH, Bergisch Gladbach, 
Germany 
Qiaquick gel extraction kit Qiagen, Hilden, Germany 
 
 
Standards, ladders Company 
1Kb Plus DNA ladder Invitrogen 
100 bp DNA  NEB, Frankfurt, Germany 
 
 
Drug Company 
Inhibitor SU5614 Calbiochem-Novabiochem, Bad Soden, Germany 
2.2. Cell lines, bacteria and biological material 
 
Mammalian Cell Lines 
Phoenix Ampho Packaging cell line (Stanford University, Medical Centre, USA) 
PG13 mouse embryonic fibroblast r packaging cell line (ATCC) 
K562 erythroleukemia cell line (ATCC) 
SLSL-J-IL3-neo-murine fibroblast (Terry Fox Laboratory, Vancouver, Canada) 
SL/SL- J-SF-tkneo J-IL-3-hytk-murine fibroblast (Terry Fox Laboratory, Vancouver, Canada) 
M2-10B4 j-GCSF-tkneo j-IL-3-hytk- murine fibroblast (Terry Fox Laboratory, Vancouver, Canada)
 
 
Bacteria 
Eschereschia coli DH5α 
Eschereschia coli BL-21 
Biological Materials Company 
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Peripheral blood (PB) AML patients  
Bone marrow (BM) AML patints  
Cord blood (CB) healthy donors  
2.3. Material for in vivo mice experiments 
In Vivo   
NOD/LtSz-scid/scid (NOD/SCID) mice  Animal House Facility at the GSF Institute for 
 Experimental Hematology  
 
 
Mice related reagents and equipement  
Avertin Solution  Sigma-Aldrich, St. Louis, MO 
Formalin soloution Sigma –Aldrich, St. Louis, MO 
Sterile Syringes BD Bioscience, Palo Alto, CA 
Kendall Monoject 3 ml syringes Tyco Healthcare, UK 
Sterile needels 0,5 x 25mm and 0.55 x 0.25 BD Microlance, Drogheda, Ireland 
Sterile needles for methylcellulose Stem Cell Technologies, Vancouver, Canada 
Ammonium Chloride solution Stem Cell Technologie, Vancouver, Canada 
Heparinized capillaries Microcuvette CB 300 Sarsted, Numbrech, Germany 
2.4. Software and machines 
Softwares Company 
CellQuest version 3.1f Becton Dickinson Immunocytometry Systemss 
 
 
Machines Company 
FACS vantage Becton Dickinson FACScan  
FACS vantage Becton Dickinson FACSort flow cytometer 
137Cs source   
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3. METHODS 
3.1. Biological materials 
Umbilical cord blood (CB) was obtained from mothers undergoing cesarean delivery 
of normal, full-term infants and collected in heparin coated syringes. Approved institutional 
procedures were followed to obtain informed consent of the mothers. Frozen CD34+ cord 
blood or bone marrow (BM) cells from healthy donors were buying by (CellSystems, St. 
Katharinen, Germany). Peripheral blood or bone marrow was obtained from 12 patients with 
newly diagnosed AML after informed consent and with the approval of the Clinical Research 
Ethics Board of the LMU University of Munich. 
3.2. Chemical material: SU5614 
The PTK inhibitor SU5614 was obtained from Calbiochem (Calbiochem-
Novabiochem, Bad Soden, Germany), dissolved in dimethyl sulfoxide (DMSO) at stock 
concentrations of 10 mM and 50 mM, aliquoted, and stored at -20 °C. Final concentrations of 
DMSO in growth medium did not exceed 0.1 %. 1x 106cell/ml frozen mononuclear PB or 
BM cells from AML patients and normal CD34+ enriched BM cells (98 % CD34 positive) 
were incubated in IMDM with 20 % FCS, at 1x106 cells/ml with 50 ng/ml G-CSF with or 
without 1–10 µM SU5614. After 24 hours incubation cells were harvested, adherent cells 
trypsinized, washed twice in IMDM with 20 % FCS and viability measured by trypan blue 
dye exclusion prior to plating in the various assays. Equal fractions of the cells recovered 
from cultures with or without the PTK inhibitor were assayed without regard to any change in 
cell numbers during the 24 hours culture period. Assays for AML-colony forming cell (CFC) 
long term initiating cells (LTC-IC) and suspension culture (SC) were performed. 
3.3. Virus producer packaging cell lines 
Phoenix Ampho cells cultured in DMEM with 10% fetal bovine serum were plated at 
2.5 x 106 cells per 10 cm plate one day before transfection. Medium was changed 4 hours  
prior to transfection.  In a 5 ml tube 20 µg of plasmid DNA, 62.5 μl of 2M CaCl2 and dH2O 
to make up to 500 μl were mixed together. 500 μl of 2x HBS was added drop wise to form a 
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precipitate within the next few minutes. This mixture was then added to the cells drop wise. 
After about 12 hours, the medium was replaced with fresh medium to collect virus particles. 
The virus containing medium (VCM) was collected  after 24 hours, filtered trough 0.45 µm 
filter, supplemented with protamine sulphate to give a final concentration of 5 µg/ml, and 
layered on PG13 packaging cells for viral infection. After repeated infections (3-5 times), 
PG13 cells were allowed to express the YFP contained in the plasmid vector for a period of 
about 48 hours & then YFP expressing cells were sorted out using FACS and cultured for up 
to 2 weeks. From these YFP+ PG13 cells, single cells were sorted into 96 well plates, 
expanded & viral production was titered using K562 cells. Individual YFP+ PG13 clones 
were tested & the clone that was producing the highest viral titer was identified & used for 
infecting umbilical cord blood derived hematopoietic cells. 
3.4. Feeders and Co-cultures 
For the normal cord blood as well as Bone Marrow long term culture initiating cells 
(LTC-ICs), a mixture of M2-10B4-J-GCSF-tkneo-J-IL3-hytk fibroblasts and SL/SL-J-SF-
tkneo-J-IL3-hytk fibroblasts were used. M2-10B4 cells are a cloned line of mouse bone 
marrow origin engineered to produce G-CSF and IL-3 (190 and 4 ng /ml respectively) and the 
SlSl fibroblasts are a cell line originally established from Sl/Sl mouse embryos engineered to 
produce high levels of soluble Steel factor with or without production of the transmembrane 
form of SF (60 and 4 ng / ml respectively). The M2-10B and the Sl/Sl cells were maintained 
by plating at a concentration of 1-2 x105 cells per 10 cm tissue culture dish (Corning) in 
RPMI, 10 % FCS, 0,4 mg/ml G418 and 0,06 mg/ml hygromicin and DMEM, 15 % FCS, 0,8 
mg/ml G418 and 0,125 mg/ml hygromicin respectively. The mixing of the two feeders was 
done at a 1:1 ratio following irradiation. 
All murine feeders were irradiated with 8000 Rads (80 Gy) before being cocultured 
with human hematopoietic cells and placed on 35 mm tissue culture dishes (Corning) pre-
coated with collagen solution (StemCell Technolgies) form a  film that help the adherence of 
fibroblast cell lines used in the LTC-IC assay. 
For the AML LTC-ICs, SLSL-J-IL3-neo-only fibroblasts originally obtained from 
Sl/S1 mouse embryos and engineered to produce human IL-3  at a concentration of 16,5 ng  
/ml. They were maintained by plating at a concentration of 1-2 x105 cells per 10cm tissue 
culture dish (Corning) in DMEM  supplemented with 15 % FCS and 0.8 mg/ml G418 
(Gibco). 
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3.5. Retroviral constructs 
HPIP cDNA was already cloned in pMSCV-IRES-GFP cassette (provided by Carolina 
Abramovich) 30,31. As a control, the MSCV vector carrying only the IRES green fluorescent 
protein cassette (GFP virus) was used. 
VENTX2 cDNA was provided by Paul Moretti (Hanson Centre for Cancer Research 
Institute of edical and Veterinary Science, Adelaide). VENTX2 cDNA was sub-cloned in 
pMSCV-IRES-GFP vector. As a control, the MSCV vector carrying only the IRES green 
fluorescent protein cassette (GFP virus) was used. High-titer, helper-free recombinant 
retrovirus was generated by first transfecting the amphotropic Phoenix cell line and 
subsequentlyto to make the stable virus producing cell line PG13 cells were transduced. High-
titer producer clones were isolated for each virus and analysis of GFP expression was tested in 
K562 cells).  
3.6. Protein expression  
Protein expression of the VENTX2 was documented by Western blotting using 
standard procedures. Total cellular protein was extracted from PG13-VENTX2 and PG13-
MIG packaging cells line by using RIPA lysis buffer. Whole cell lysate were separated on 12 
% SDS-page gel and transferred to nitrocellulose membrane. Membranes were probed with an 
anti-VENTX2 polyclonal antibody (kindly provided by Richard J. D.’Andrea, Departement of 
Medicine Adelaide, Australia) 35. The membrane was reprobed with secondary goat anti-
rabbit immunoglobulin labeled with horseradish peroxidase. Proteins were visualized using an 
ECL plus kit, according to manufacturer’s recommendations.  
3.7. Purification of human CB CD34+ cells 
Umbilical cord blood was collected in heparinised syringes according to institutional 
guidelines following normal full-term deliveries. Informed consent was obtained in all cases. 
Mononuclear cells (MNC) were separated using density gradient centrifugation. Fresh 
umbilical cord blood, not older than 12 hours, was diluted with 2 volumes of PBS and layered 
over Pancoll. Usually 35 ml of diluted blood was layered over 15 ml Pancoll in a 50 ml 
conical tube. This was centrifuged at 400x g for 30 minutes at 20°C in a swinging-bucket 
rotor without brakes. The upper layer was aspirated and discarded, leaving the interphase 
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undisturbed. The interphase containing MNC such as lymphocytes, monocytes and 
thrombocytes was then transferred to a new 50 ml tube, washed twice with large volumes of 
PBS, and then counted before labeling with magnetic bead or fluorochrome conjugated 
antibodies. 
CD34+ cell purification was conducted using MACS CD34 Cell Isolation Kit that uses 
positive selection method. Cells were resuspended in a volume of 300 μl per 108 cells, 
blocked with 100 μl of FcR Blocking Reagent and labeled with 100 μl of CD34 Microbeads. 
When working with higher cell number, all the reagent volumes & the total volume was 
scaled up accordingly. This was followed by incubation for 30 minutes at 4-8°C. Cells were 
then washed twice by adding 10x the labeling volume of buffer and centrifuged at 300 x g for 
15 minutes. The resultant cell pellet was then resuspended in 500 μl of MACS buffer and 
loaded into MS Column mounted on magnetic separator. The negative cells were allowed to 
pass through and the column was washed at least three times with 2 ml buffer. The column 
was then removed from the separator, placed on a collection tube, loaded with fresh buffer, 
and the magnetically labeled cells flushed out using the plunger. The magnetic separation was 
usually repeated to get a purity of more than 95%. Purified cells were then frozen in FBS with 
10% DMSO and thawed when needed for pre-stimulation and transduction. 
CD34+ cell enrichment was done either by MACS or by FACS. For separation by 
FACS, MNCs were thawed from frozen stocks or prepared freshly from UCB and labeled 
using anti CD34-PE antibody (100 μL per 108 cells), for 30 minutes on ice. Labeled cells 
were then washed twice with PBS, resuspended in FACS buffer and sorted. The sorted cells 
with purity above 95 % were used for 48 hour pre-stimulation followed by transduction. 
 
3.8. Transduction of Human cord blood Cells 
Enriched CD34+ cord blood (CB) cells were thawed and count. 2 ×106/ml cells were 
pre-stimulated for 48 hours in Iscoves modified Dulbecco medium (IMDM) containing a 
serum substitute (BIT, Stem Cell Technologies, Vancouver, BC, Canada) 10 4M 
mercaptoethanol (Sigma), and 40 µg/ml low-density lipoproteins (Sigma) supplemented with 
the following recombinant human cytokines: 100 ng/ml Flt-3 ligand (L; PAN Biotech GmbH, 
Aidenbach, Germany), 100 ng/ml Steel factor (SCF; ImmunoTools Friesoythe; Germany), 20 
ng/ml interleukin-3 (IL-3; ImmunoTools), 20 ng/ml IL-6 (Tebu-bio, Frankfurt, Germany) and 
20 ng/ml granulocyte colony-stimulating factor (G-CSF; Stem Cell Technologies). After 48 
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hours cells were resuspended in filtered virus-containing medium (VCM) supplemented with 
the same cytokines combination and protamine sulfate (5 µg/ml) on tissue culture dishes, 
preloaded twice with VCM, each time for 1 hour (Corning, Acton, MA). This procedure was 
repeated on the next 2 consecutive days for a total of 3 infections. For in vitro studies, 
aliquots of these cells were transferred to fresh serum-free medium plus the same additives 
and cytokines and then incubated for an additional 48 hours prior to being stained with PE-
labeled anti-CD34 antibody (Becton Dickinson, San Jose, CA) and isolation of the 
YFP+/GFP+/ CD34+ cells on a FACS Vantage (Becton Dickinson) sorter. For in vivo studies, 
transduced cells were injected into non obese diabetic/severe combined immunodeficiency 
(NOD/SCID) mice immediately after transduction (< 6 hours after the last exposure to fresh 
VCM) without pre-selection. 
3.9. Liquid culture of Transduced Cord Blood Cells 
For in vitro liquid expansion assays, transduced cord blood CD34+VENTX2/GFP+ cells 
and CD34+ MIG/GFP+ cells were placed in cytokine-supplemented serum-free medium 
containing 10-4M 2-Mercaptoethanol, (Gibco) 20 % BIT (StemCell). For Cord blood 
transduced cells 100 ng/ml each of Flt-3 ligand and SF and 20ng/ml each of IL-3, IL-6 and G-
CSF was added. Half-media change was performed every week and morphology of cells 
present in cultures at various time points was determined by performing cytospin. For this 
step 1x 105 cells were fixed on slide and stained with Wright-Giemsa. Every week 1x 104 
cells were plated in CFC assay after half-media change. In addition, separate aliquots were 
taken and incubated for 30 minutes on ice with a mouse isotype-matched control antibody 
(Becton Dickinson) and antibodies against human antigens and analyzed by FACS for the 
expression of different lineages. 
3.10. Suspension culture initiating cells (SC-IC) assay for 
AML cells  
AML cells or normal BM cells were incubated at a concentration of 1x 106 cells/ml in 
serum free media containing 10-4M 2-Mercaptoethanol, 2mM glutamine and a cocktail of 
growth factors in IMDM with 20 % BIT (StemCell). For AML cells 20ng/ml each of IL-3, IL-
6, G-CSF, and GM-CSF and 50ng/ml SF was used and for normal marrow cells 100 ng/ml 
each of Flt-3 ligand and SF and 20ng/ml each of IL-3, IL-6 and G-CSF was added along with 
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40 µg/ml low density lipoproteins. After 6 wks with weekly half medium changes, cells were 
harvested by trypsinization and placed into AML-CFC methylcellulose medium or normal 
CFC (Methocult H4330, Stem Cell Technology) supplemented with 3 U/ml Epo, 50 ng/ml SF 
and 20 ng/ml each of IL-3, GM-CSF, G-CSF (Amgen, Thousand Oaks, CA) and IL-6 
(Cangene, Mississauga, Ontario). Granulopoietic, erythroid and mixed colonies were detected 
and counted after 16 days of incubation at 37°C. 
3.11. In vitro progenitors assay for normal and AML cells: 
Colony-Forming Cells (CFC)  
Assays for in vitro colony-forming cells (CFCs) for tranduced CD34+ CB cells were 
carried out in methylcellulose cultures (GF H4434; 0.92 % methylcellulose, 30 % FCS, 2mM 
L-glutamine, 10-4M 2-mercaptoethanol, 1 % BSA in IMDM; Stemcell Technologies) 
supplemented with 50 ng/ml human SF, 20 ng/ml each of human IL-3, IL-6, GM-CSF 
(Novartis) and G-CSF and 3 U/ml erythropoietin (Stemcell Technologies). Secondary CFC 
assays were performed by replating aliquots of cells obtained by harvesting primary CFC 
dishes. 
CFC assay for AML-CFC were performed plating 1 to 2 x105 cells/ml in 
methylcellulose medium (GF H4430; Stemcell Technologies) supplemented with 3 U/ml 
human erythropoietin (Epo, StemCell), 10 ng/ml GM-CSF, 10 ng/ml IL-3, 50 ng/ml Steel 
factor (SF) (Terry Fox Laboratory) and 50 ng/ml Flt-3 ligand (all Tebu-bio GmbH, 
Offenbach, Germany). Cultures were scored after 14 days for the presence of clusters (4-20 
cells) and colonies (more than 20 cells). 
3.12. Long term culture-initiating cells (LTC-IC) assay for 
AML and Normal Bone Marrow cells 
Six-week long-term culture-initiating cell (LTC-IC) assays were carried out using 
AML cells co-cultured in Myelocult H5100 LTC media (CellSystems) supplemented with 
106M solucortef (Sigma-Aldrich, Taufkirchen, Germany) with a supportive feeder layer of 
murine fibroblast cell lines (Sl/Sl-J-IL3) irradiated at 80Gy and then seeded into new 
collagen-coated tissue culture dishes at 2.2 x105cells/dish. Sl/Sl fibroblasts consist of Sl/Sl 
mouse embryos. Sl/Sl-J-IL3 fibroblasts were obtained by transduction of Sl/Sl fibroblast with 
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a human IL3 cDNA containing retrovirus. These cells produce bioactive human IL3 at a 
concentration of 16ng/ml as determined by the ability of their growth medium to stimulate 
3H-thymidine incorporation into Mo7e cells, an IL3-dependent cell line Otsuka et al (1991). 
LTC-IC was incubated at 37°C in 5 % CO2 and received weekly one half-media changes. In 
LTCs which were supplemented with SF of FL, the weekly half-medium change contained 
the cytokine of interest at twice the final concentration (50 ng/ml). After 6 weeks both, 
adherent and non adherent cells were trypsinized, pooled and plated in methylcellulose as 
described above. The number of CFC per million cells initially plated in LTC could then be 
calculated as follows: 
 
In this way CFC output could be standardized to allow comparison of different culture 
condition. To detect normal LTC-IC human BM cells were plated onto preformed mix feeder 
layers of irradiated Sl/Sl j-SF-tkneo j-IL-3-hytk and M2-10B4 j-GCSF-tkneo j-IL-3-hytk cell 
lines genetically engineered to produce SF, G-CSF and IL-3, with weekly half-media changes. 
After 6 weeks adherent and non adherent cells were harvested and assessed for their AML-
CFC or CFC has described above. 
3.13. Limiting Dilution LTC-IC assay 
M2-10B4 G-CSF / IL-3 and Sl/Sl SF / IL-3 cells (1:1 mixture) were established in 96-
well flat-bottom culture plates at a density of 1,25 x 104 cells. On the day of assay, HLTM 
was removed using multi-channel pipette or with sterile tips and discarded. The test cells were 
added to the wells in 0,2 ml of HLTM with solucortef. The number of cells seeded per well is 
indicated in table 3,3. LTC-IC cultures were incubated at 37°C in humidified incubator 
(>95%) with 5 % CO2 in air for six weeks. For weekly half media exchanges, one half of the 
medium and cells were removed and replaced with HLTM for five weeks. To harvest the 
LTC-IC, the HLTM and non-adherent cells were removed from wells and place into 
individual 12x75 mm sterile tubes using a pipette and sterile tips. Single wells were harvested 
at a time to avoid cross contamination of samples. Wells were rinsed once with 0,2 ml PBS 
and added to tube. 0,1 ml Trypsin-EDTA was added to each well and incubated for 3 to 5 
minutes and examined for detached cells. Once the adherent cells are detached, the wells are 
washed with more PBS and the medium collected in the appropriated tube. The wells are 
#cells plated in LTC at time 0
#cells/LTC at harvest#CFC/dish MeCell
#cell plated in  MeCell
X X 10 = CFC/106 cells
plated at time 0
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finally washed with 0,2 ml IMDM containing 2 % FBS and transferred to the appropriate 
tube. The tubes were centrifuged at 1200 rpm for 10 minutes and the supernatant removed 
without disturbing cell pellet. Approximately 0,1 ml of medium was left along with the cell 
pellet and vortexed. To this 1 ml of Methocult (H4435) methylcellulose medium was added 
and vortexed again. Each tube (contents of one well) was plated individually into 35 mm petri 
dish with 1 ml syringe (without needles attached). Several dishes (6-8) were placed in a 15 cm 
petri-dish along with an additional 60 mm open dish containing 5 ml sterile water to maintain 
humidity. The dishes are incubated at 37°C in humidified incubator (>95 %) with 5% CO2 in 
air for 12 to 16 days. Colonies were counted and a well scored as positive if one or more E-
BFU, GM-CFU or G-CFU GEMM-CFU were detected or scored as negative if no colonies 
were present. The LTC-IC frequency in the test cell population was calculated from the 
proportion of negative wells (no CFC present) and the method of maximum likelihood. 
Statistical analysis was performed using L-Calc™ software for limiting dilution analyses. 
3.14. Screening for the LM and the mutations at codon 
835/836 in the FLT3 gene 
Analysis of Asp835/836 mutations was performed using the restriction fragment gene 
length polymorphism at codon 835/836 exactly as described previously 102. After 
amplification of a 114-bp fragment from exon 20 using gDNA, polymerase chain reaction 
(PCR) products were digested by EcoRV and separated on an 8% polyacrylamide gel. 
Undigested bands were cut out from the gel, purified with a Qiaquick gel extraction kit 
(Qiagen, Hilden, Germany), and directly sequenced on a DNA sequencer (ABI PRISM 310  
Genetic Analyzer; Perkin Elmer; obtained from Applied Biosystems, Weiterstadt, Germany) 
using a Big Dye terminator cycle sequencing kit (Applied Biosystems, Darmstadt, Germany). 
Screening for FLT3LM was performed as described by Nakao et al.(1996) 94.  
3.15. NOD/SCID Mice 
NOD/LtSz-scid/scid (NOD/SCID) mice were bred and maintained in the animal 
facility of the GSF (Haematologikum) in microisolator cages containing autoclaved food and 
water. Seven to eight week old NOD/SCID mice were sublethally irradiated with 275 cGy 
from a 137Cs source one day prior injection. For transplantation, transduced cells were 
washed, counted, resuspended in PBS and injected into the lateral tail vein of irradiated mice 
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(300-400µL/mouse). Bone marrow cell aspirates were performed 3, 6 and 10 weeks after 
transplantation following anesthesia with Avertin (2,2,2 – Tribromoethanol, Sigma Aldrich , 
St. Louis, MO) 11 µl/g mouse injected i.p. Cells were stored in Alpha MEM with 50% FCS 
and used for FACS staining. After 6-18 weeks mice were sacrificed by CO2 inhalation. The 
cells from both tibiae and femurs of each mouse were collected for additional analyses. The 
absolute number of cells in the marrow of each mouse was calculated assuming that the 
contents of both femurs and both tibiae represent 25% of the total marrow. 
3.15.1 Analysis of mice 
Cells harvested from bone marrow of NON/SCID mice were harvested, resuspended 
in 7 % ammonium chloride (Stem Cell Technologie, Vancouver, Canada) and placed on ice 
for 20 minutes to lyse red blood cells. Afterwards, cells were washed again and resuspended 
in Hanks balanced salt solution (Stem Cell Technologie, Vancouver, Canada). Cells were 
washed and stained with anti-human CD45-PE (Becton Dickinson). A proportion of  the cells 
were incubated 30 minutes on ice with a mouse IgG1 isotype control (Becton Dickinson 
Immunocytometry Systems, San Jose, CA) to evaluate nonspecific immunofluorescence. The 
remaining cells were incubated with fluoresceinated anti-CD45 a human-specific pan-
leukocyte marker to detect human cells. The percentage of CD45+ cells was determined after 
excluding 99.9 % of nonviable (propidium iodide [PI]) cells and at least 99.9 % of cells 
labeled with isotype control antibodies. To determine lineage differentiation and multilineage 
engraftment, cells were stained for 30 minutes at 4°C, with the antihuman CD45-PE.  
phycoerythrin (PE;Becton Dickinson) and antihuman CD71-APC antibodies (OKT9) to 
quantitate the total number of human cells present (CD45+/71+), with antihuman CD34 8G12-
Cy5 and antihuman CD19-PE to quantitate the number of human B cells present, and with 
antihuman CD15-PE (Becton Dickinson) to quantitate the number of human myeloid cells 
present. Additional antibodies used for the detection of erythroid positive cells fraction were 
the antihuman GlyA-PE and antihuman CD36-APC (Becton Dickinson), and antihuman 
CD38- PE (Becton Dickinson). Expression of basophiles was detected using CD25-APC (IL-
2Rα), antihuman CD40-APC and Cd11b-PE and antihuman CD41a-PE (Becton Dickinson). 
Multilineage engraftment was considered if there were >5 CD34+CD19+ human cells 
and > 5 CD45+/CD15+ human cells per 2x104 viable cells analyzed (Holyoake TL, Nicolini 
FE, Eaves CJ. Functional differences between transplantable human hematopoietic stem cells 
from fetal liver, cord blood, and adult marrow. Exp Hematol. 1999;27:1418-1427).  
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3.16. Flow Cytometry and Cell Sorting 
To determine the gene transfer efficiencies of cultured CD34 cord blood cells after 
transduction, aliquots of cells were stained with anti-human CD34-Cy5, washed twice with 
PBS and stained with propidium iodide 2µg/mL to exclude non-viable cells. Subsequently, 
cells were analyzed using a FACS Calibur (Becton Dickinson) with Cellquest software 
(Macintosh, Cupertino,CA). 20.000 events were acquired to determine the proportion of 
positive cells present; positive cells were defined as those exhibiting a level of fluorescence 
exceeding 99.98% of that obtained with isotype-control antibodies labeled with the same 
fluorochromes. Green fluorescent protein (GFP) positive cells were detected by their 
increased fluorescence intensity within the fluorescence 1 channel. Gene transfer efficiencies 
were calculated by dividing the number of GFP+CD34+ cells by the total number of CD34+ 
cells.  
3.17 Statistical analysis 
Data were statistically tested using Student’s t-test for dependent or independent 
samples (software STATISTICA 5.1, StatSoft Inc, Tulsa, USA). Differences with p-values < 
0.05 were considered statistically significant. 
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4. RESULTS 
4.1 The human non-homeobox hematopoietic PBX 
interacting protein HPIP 
4.1.1 Efficient retroviral gene transfer of HPIP in normal human 
hematopoietic progenitor cells  
The complete cDNA of the PBX interacting protein HPIP was cloned into the 
bicistronic vector with an IRES - GFP cassette based on the murine stem cell virus (MSCV) 
viral backbone (HPIP - virus). The MSCV –IRES – GFP vector was used as a control (GFP 
virus)(Fig.1a). High titer clonal viral producer cells were generated from the GALV 
pseudotyped PG13 packaging cell line for both viruses. Full-length proviral integration and 
expression was confirmed by Southern blot, use RT – PCR and Western blot analysis (Fig. 
1b). The mean transduction efficiency was 61% (55 – 67%) and 35% (29 – 41%) in primary 
CB cells with the GFP and HPIP - GFP virus, respectively (n=9). We did not see differences 
in the percentage of CD34+ cells in the transduced GFP+ fraction between both experimental 
arms. 
4.1.2 HPIP decrease proliferation of hematopoietic progenitors in vitro  
As an initial test to determine whether HPIP would affect the proliferative capacity of 
human hematopoietic progenitor cells, 1 x 104 cells highly purified CD34+/HPIP-GFP+ and 
CD34+/GFP+ progenitor populations were cultured in serum free medium supplemented with 
cytokines for 4 weeks. Constitutive expression of HPIP decreased viable cell numbers at 
every time point from week 1 to 4 with a mean 2.1fold (+ 0.3) decreased cell count 
(p<0.05)(n=5): HPIP expressing cells expanded 803 fold (± 395) after 2 weeks of culture 
compared to a 1638 old (± 614) expansion within the GFP control arm (p=0,03). After 3 
weeks of in vitro culture on average a 1155fold (± 695) expansion was obtained in the HPIP 
compared to a 3675 fold (± 1184) expansion in the GFP control arm (p=0,04).  
 
 
After 4 weeks the the proliferative disadvantage for human progenitors overexpressing  
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HPIP was still demonstrable, although to a lesser extent (3106fold for HPIP versus 4637 fold 
expansion for GFP (±2327 fold and ± 1946fold respectively). Thus, over time constitutive 
expression impaired cell expansion in vitro by > 50 % (57.7 + 4.7) with up to 70.4 % week 3 
(Figure 4.1).  
Figure 4.1. Expansion kinetics for human progenitor cells in liquid expansion 
experiments. HPIP-GFP and GFP transduced CD34+ cells were cultured in serum free medium 
supplemented with cytokines for 4 weeks. Expression of HPIP was determined at every time point 
from week 1 to 4. 
4.1.3 Expression of HPIP decreases the frequency and proliferative 
capacity of clonogenic progenitors in short-term in vitro assays. 
In a second step we wanted to assess whether HPIP would decrease the number of 
clonogenic progenitors during short-term in vitro expansion. When the frequency of 
clonogenic progenitors was determined after 7 days of in vitro culture in serum free medium 
supplemented with cytokines HPIP expression was associated with a 24 % lower frequency of 
CFC compared to the control (26 CFC/1000 cells ± 7 and 34/1000 cells  ± 10, 
respectively)(n=4). When the absolute numbers of clonogenic progenitors were calculated for 
this time point HPIP expression decreased the CFC number 5.7 fold (range 0.8 – 15, n=4). In 
order to test the impact of HPIP expression on clonogenic progenitors in a different assay 
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system, HPIP-GFP and GFP – infected CD34+ progenitor cells were plated into 
methylcellulose and colony formation was evaluated after 14 days: HPIP expressing 
progenitor cells formed 209 (+ 16.6) colonies / 1000 cells initially plated versus 222 (+ 27.9) 
colonies in the control (n=6). However, the lineage distribution of colonies differed 
significantly with more erythroid colonies in the HPIP transduced cord blood cells vs. the 
GFP control (34 BFU/CFU-E / 1000 cells initially plated, [19 – 50] in HPIP+, vs. 18 
BFU/CFU-E / 1000 cells initially plated, [5 – 34] in the GFP control arm, p < 0,00003). In 
contrast, no significant differences were observed in the formation of GM-CFU or GEMM-
CFU colonies. When aliquots of primary methylcellulose dishes were re-plated HPIP 
expression decreased the number of secondary colonies 8fold (range 2-12 fold) with a mean 
number of secondary colonies of 2.2 x 103 colonies / 1000 cells initially plated versus 18.8 x 
103 colonies in the control (n=4). The mean reduction of secondary colony formation was 79 
% (+ 9.4) ranging from 51 % up to 92 % (p < 0.004). 
4.1.4 HPIP increases the frequency of primitive progenitor cells in long-
term in vitro cultures.  
As we had seen that HPIP expression had a major impact on progenitor behavior in 
vitro we wanted to test the influence of HPIP expression on the maintenance of human 
progenitors in long-term cultures. First we determined the frequency and the yield of 
clonogenic progenitors in serum free liquid culture supplemented with cytokines plating 
aliquots of cells after 1-6 weeks, weekly into methylcellulose. Intriguingly, HPIP expression 
induced a 3.9 fold and a 3.4fold increase in the CFC frequency after 3 and 6 weeks, 
respectively. The mean frequency was 48.1 (20-102) CFC / 1000 plated cells with HPIP 
versus 12.4 (6-16) CFC / 1000 plated cells in the control (n=3) at week 3 and 7.2 (1.5-16) 
versus 2.2 (0.5 – 4.5) at week 6 (n=4)(Figure 4.2).  
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Figure 4.2 Colony Forming Cells (CFC) assy. CFCs colonies were scored after four and six 
weeks and the increase of clonogenic progenitors was determined in cells transduced with HPIP vs. 
the empty control. Frequency and refer to the number of CFCs per 1000 cells plated initially and yield 
indicates the total number of CFCs generated per arm was analyzed with Poisson statistic *p<0.02. 
 
 
As HPIP transduced cord blood cells were able to increase the yield of CFC compared 
to the control we next asked whether HPIP expression would also have an effect of human 
stem cell pool size. Thus, we analyzed the impact of HPIP at the level of the long-term 
culture initiation cell (LTC-IC), the in vitro equivalent of repopulating stem cells. Highly 
purified CD34+GFP+ and CD34+ HPIP-GFP+ cells from 5 independent cord blood samples 
were cultured for 7 days in serum free medium supplemented with cytokines and transferred 
into long term culture conditions by plating on murine stromal fibroblasts engineered to 
produce human SF, IL-3, and G-CSF under LTC-IC conditions. Two of the 5 assays were 
performed as limiting dilution LTC-IC assays, to calculate the LTC-IC frequency and the 
CFC output per LTC-IC under HPIP-GFP versus GFP expression. Using limiting dilution 
settings in two experiments and calculating the LTC-IC frequency for all 5 independent 
analyses referred to the cell equivalent after 7d of liquid culture extended and enhanced 
expression of HPIP induced a median 4.8 fold increase ranging from 2 to over 140 fold (p < 
0.02)(Figure 4.3). 
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Figure 4.3. Limiting dilution assay (LDA-LTC-IC). After pre-cultivation in liquid culture 
CD34+HPIP+GFP+ and CD34+GFP+ transduced cord blood cells were placed on a monolayer of feeder 
cells in 96 well plates. Cultures were maintained with a weekly half-media change. After six weeks 
each well was harvested and cells were plated into methylcellulose. After two weeks the number of 
growing colonies was scored. The frequency of LTC-IC was determined as described in the text.  
p<0.02. 
 
 
When the total yield of CFC per 1x104 initially plated cells was calculated HPIP 
increased the CFC output over 12 fold with a mean of 69 CFC (± 41) versus 5.6 CFC (± 2.3). 
This increase associated with constitutive HPIP expression was confirmed when the number 
of LTC-IC derived CFC was calculated for the 3 bulk LTC-IC assays: HPIP increased the 
CFC output over 13 fold with a mean of 2.66x 104 versus 0.195 x 104 per 106 cells for HPIP 
versus GFP, respectively (p<0.04) (Figure 4.4).  
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Figure 4.4. The constitutive expression of HPIP enhances the frequency of bulk LTC-IC. 
 
To determine, whether this increase was mainly due to the increase of the LTC-IC 
frequency or caused by a higher production of CFC per LTC-IC, the CFC output per LTC-IC 
was calculated. We could detect a somewhat lower output of CFC/LTC-IC for the HPIP 
transduced cells with 22 vs 33 CFC per LTC-IC for HPIP and GFP, respectively (Figure 4.5). 
 
Figure 4.5 Constitutive expression of HPIP decreases LTC-IC derived CFC. P=ns, not significant.
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4.1.5 The constitutive expression of HPIP enhances the proportion and 
number of engrafted human myeloid cells in NOD/SCID mice 
As we had seen that HPIP affected lineage differentiation and expanded human 
progenitor cells in vitro we extended our studies in vivo using the xenograft NOD/SCID 
mouse model. In order to determine whether gene transfer of HPIP into repopulating stem 
cells would be efficient and allow reasonable levels of long-term engraftment, cohorts of 
sublethally irradiated NOD/SCID mice were injected with the CB progeny of a day 0 input 
number between of 8.3 x 104 - 14 x 104 CD34+ cells per mouse immediately post-infection 
without any pre-selection of CD34+ GFP+ cells in two independent experiments. Engraftment 
with human transduced or non-transduced cells was first assessed by FACS analysis of bone 
marrow cells obtained by femoral bone marrow aspirate at week 3, 6, and at 14 weeks when 
the mice were sacrificed.  
Already at week 3 the majority of mice in both experimental arms engrafted with 
human transduced cells (4/4 mice and 2/4 mice (>0.1 % CD45+/GFP+) in the HPIP and GFP 
arm control, respectively). Human engraftment was stable and at week 6 7/8 control mice and 
all HPIP mice (12/12) were engrafted with human lymphoid and myeloid cells and none of 
the animals of both experimental groups lost lymphomyeloid engraftment at week 14 (5/7 
mice in the control group and 12/12 in the HPIP).   
The engraftment level of transduced human cells at week 14 ranged from 0.2 – 18.05 
% and from 0.1 – 9.3 % GFP+CD45+ cells for GFP and the HPIP group, respectively. Both 
experimental groups showed lymphoid predominance of engrafted human cells with 
lymphoid/myeloid ratios > 1 as previously reported. Thus, we achieved reasonable long-term 
lymphomyeloid engraftment in both experimental groups, indicating efficient gene transfer 
into long-term repopulating stem cells. Furthermore, constitutive expression of HPIP was 
permissive for lymphoid/myeloid differentiation in vivo.  
When a more refined analysis of the proportion of human transduced B cells 
(GFP+/CD19+/CD45+) and myeloid cells (GFP+/CD15+/CD45+) was performed there was a 
trend towards a higher proportion of transduced human myeloid cells at the early time point of 
week 3 (p<0.06). At week 6 HPIP induced a significant increase in the proportion of 
engrafted myeloid cells (24 % vs 10 % in the control; p<0.005) and a significant decrease of 
engrafted lymphoid cells (35 % vs. 58 % in the control; p<0.04) within the transduced 
compartment compared to the GFP control group (Figure 4.6).  
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Figure 4.6 HPIP enhances the proportion of human myeloid cells in Transplanted 
NOD/SCID mice. Six weeks post transplantation bone marrow aspiration was performed on HPIP-
GFP and GFP transduced NOD/SCID mice. Cells were detected for lineage engraftment by flow 
cytometry. 
 
At the late time point of 14 weeks post transplantion the difference in the proportion of 
human transduced B cells was stable with 33 % versus 56 % GFP+/CD19+ cells in the HPIP 
and the GFP group, respectively (p=0.03). When the total number of transduced lymphoid and 
myeloid cells was calculated for both experimental groups, there was a 20 % increase for 
human myeloid cells and a 20% decrease in human lymphoid cells within the transduced 
compartment for HPIP compared to the control (ns). The effect of HPIP on B cells was 
further confirmed when the proportion of mature CD20+ B cells was quantified: at the early 
time point week 3 mice of the HPIP group had significant decreased percentage of CD20+ 
cells in the transduced compartment compared to the control (3.8 % versus 42.2 % in the 
control; p<0.004); at week 6 and week 14 HPIP decreased the proportion of GFP+/CD20+ 
cells by 34 % and 33 % respectively. When the absolute numbers of transduced CD20 
positive cells were calculated for week 14 the HPIP mice had a mean of 3.5 x 105 cells (+ 1.2) 
versus 14.6 x 105 cells (+ 9.8)(ns).  
Most intriguingly, constitutive expression of HPIP increased the proportion and 
absolute cell number of early hematopoietic progenitor cells characterized by expression of 
the CD34 antigen: HPIP expression increased the proportion of CD34+/GFP+ cells by 83 % 
compared to the control (2.9% ± 0.9 vs. 1.6 % ± 0.7). In addition, the absolute number of this 
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immature cell population was increased by 117 % per mouse (0.48 x 105 ± 0.3 cells and 1.04 
x 105 ± 0.4 per mouse for the control and the HPIP group, respectively).  
4.1.6 cDNA microarray analysis from AML samples and normal bone 
marrow from healthy donors. 
In order to investigate the malignant transformation of cells it is important to first 
understand the mechanisms of normal hematopoiesis. Thus, fresh bone marrow samples from 
healthy volunteers as well as bone marrow samples from thoroughly characterized patients 
with newly diagnosed and untreated AML as defined by the World Health Organization 
classification were used and processed immediately as described by Schoch et al 2002 147 to 
perform comparative microarray analysis. 
Samples were analyzed by cytomorphology, cytochemistry, immunophenotyping, 
cytogenetic, and molecular genetics in all cases and were characterized by specific 
chromosomal aberrations or molecular genetic alterations from the leukemia diagnostics 
laboratory, Klinikum Großhadern, Munich. The studies were done in accordance with the 
rules of the local internal review board and the tenets of the revised Helsinki protocol 
Using cDNA microarrays, we have first evidence that HPIP is highly expressed in 
AML patients’ bone marrow with specific cytogenetic aberrations (FLT3 length mutation and 
acute promyelocytic leukemia AML M3 and M3v) as compared to bone marrow from healthy 
donors as well as compared to other cytogenetic subtypes (MLLPTD, complex, AMLM2 and 
M4Eo). These data point to a potential role of HPIP in AML( Figure 4.7).  
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 Figure 4.7 Level of expression of HPIP in cytogenetic subgroup of patients with AML. Bone 
marrow samples from patients with newly diagnosed and untreated AML and fresh bone marrow 
samples from healthy volunteers were analyzed. Expression of HPIP was found to be significantly 
high express in AML samples from patient carrying different cytogenetic aberrations (N=9). 
Significance was determined by Student’s t-test and is indicated above the respective bars. *P < 0.01, 
**P < 0.001, indicate statistically significant differences from the normal bone marrow used as 
control. 
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4.2. VENTX2 as a stem cell relevant gene 
 4.2.1. Efficiency of retroviral gene transfer  
 In attempt to characterize the functional relevance of VENTX2 expression in 
hematopoietic development we retrovirally transduced human cord blood cells with either 
VENTX2 or the empty GFP control vector (see Methods 2.5). The mean transduction 
efficiency was 24.07 % ± 11.13 % for VENTX2 and 52.68 % ± 21.45 % for the empty vector 
control (GFP), respectively (p<0.001) (Figure 4.8). 
 
 
 
Figure 4.8. Efficiency of retroviral transduction in human hematopoietic CD34+ cord 
blood cells. Cord blood cells were analyzed seven days after start of transduction (n=15). p<0.001 
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4.2.2. Western Blot Analysis of VENTX2 protein 
To confirm the expression of VENTX2 we used polyclonal antisera against the N-
terminal region of VENTX2 and carried out western blot analysis of cell lysates from PG13-
VENTX2 and PG13-GFP. The antisera detected the expressed 28-kDa VENTX2 protein in 
PG13-VENTX2 cells, which was not detectable in the PG13-GFP control (Figure 4.9). 
 
 
 
Figure 4.9 Western Blot analysis of the VENTX2 protein. The VENTX2 protein was 
detected with VENTX2 antisera in PG13 cells after retroviral infection.  
4.2.3. VENTX2 inhibits the formation of erythroid colonies and 
significantly increases the production of myeloid colonies in clonogenic 
progenitor cell assays.  
To detect the effect of VENTX2 expression on clonogenic progenitor cells, we sorted 
CD34+ cord blood (CB) cells transduced with VENTX2/GFP+ or GFP+ and plated them in 
methylcellulose. After 14 days of culture GEMM-CFU (Colony Forming Unit-Granulocyte, 
Erythrocyte, Macrophage and Monocyte) as well as lineage committed precursors GM-CFU, 
M, BFU-E CFU-E (Colony Forming Unit-Granulocyte-Macrophage, Monocyte) and Burst-
Forming Unit-Erythroid (BFU-E) were detected. The total number of CFCs was reduced in 
the VENTX2 transduced cells as compared to the control. This was due to an almost complete 
reduction of erythroid colony formation generated by VENTX2-transduced cells (p<0.05) 
leading to a 4.25 fold decrease compared to the GFP control cells, VENTX2 14,8, GFP 63, 
respectively (Fig. 4.10).  
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Figure 4.10 CFC assay. (A) Macroscopic picture showing the difference in growth of 
erythroid colonies in the GFP control compared to VENTX2 transduced CB cells (B). Microscopic 
picture (10x) from a single BFU-E colony.  
 
In contrast to the effect of VENTX2 on erythroid differentiation, we observed a 
significant increase of myeloid colonies when cord blood cells transduced with VENTX2 were 
analyzed and compared to the GFP control: the production of granulocyte colonies (G-CFU) 
was significant. 
Figure 4.11. Primary CFC assay. Mean number (± SEM) of colonies formed after 14 
days: CD34+VENTX2/GFP+ compared to CD34+GFP+ transduced cells (n=9).  
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To test the proliferative potential of the clonogenic progenitor cells we performed 
secondary CFC assays by re-plating cells from primary CFC assays in methylcellulose (n=6). 
VENTX2 transduced cells did not increase the total number of 2nd CFCs as compared to the 
control (n=6; VENTX2 mean = 126,8 colonies, GFP mean =131,1 colonies/1000 input cells 
plated in the primary CFC; p=ns). However, we observed a trend for an increase in the 
number of myeloid colonies generated from VENTX2 transduced cord blood cells as 
compared to the control (Figure 4.12): The number of G-CFU colonies (VENTX2 15,1 ± 6,35 
versus GFP 11 ± 4,51) as well as the number of M-CFU colonies per 1000 input cells in 
primary CFC assays (VENTX2 73,3 ± 30,21 versus GFP 36,9 ± 15,10) generated by VENTX2 
transduced cells were increased by 1,4 fold and 2 fold, respectively, as compared to the 
control. Interestingly, we could again observe a decrease of erythroid colonies (BFU-E) by 
15,5 fold as compared to the control (VENTX2 1,6 ± 0,67 versus  GFP 25,3  ±  10,35).  
  
Figure 4.12. Secondary CFC assays. Cells from primary methylcellulose dishes were 
harvested on day 14, washed twice and resuspended in IMDM 2% FCS. These cells were immediately 
replated in secondary methylcellulose plates and scored after further 14 days of culture (n=6); p=ns). 
Bars represent the mean (± SΕΜ) number of 2nd CFC from six independent experiments. 
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4.2.4. The constitutive expression of VENTX2 does not change the 
number and differentiative potential of primitive hematopoietic 
progenitor cells  
As a test to determine whether VENTX2 would affect the proliferative capacity of 
human hematopoietic progenitor cells, 2 x 104 cells highly purified CD34+/VENTX2-GFP+ 
and CD34+/GFP+ progenitor populations were cultured in serum free medium supplemented 
with cytokines for 4 weeks. There was no significant difference in the total number of cells 
generated after 4 weeks of in vitro expansion culture between VENTX2 transduced cord blood 
cells and the GFP control (VENTX2 1,2x106 ± 5,6x105 vs. GFP 1,3x106 ± 5,8x105, n=5). In 
addition, the clonogenic potential of cells from liquid culture was tested by plating aliquots of 
cells each week in methylcellulose assays. The number and distribution of all colony types did 
not change significantly over a time of 4 weeks.   
4.2.5. Limiting dilution assay 
The Limiting Dilution Analysis (LDA-LTC-IC) was used to determine the frequency 
of Long-Term-Culture-Initiating Cells (LTC-IC) as well as the average number of colony-
forming cells (CFC) produced per LTC-IC. When the effect of VENTX2 on the frequency of 
LTC-IC was determined by limiting dilution assays (n=2), no major differences were detected 
between the VENTX2 transduced cells and the control arm (453 LTC-IC vs. 801 LTC-IC per 
1x 106 cells, respectively; p = n.s.) (Figure 4.13).  
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Figure 4.13. Limiting dilution long term-initiating cells (LDA-LTC-IC) assay. The 
frequency of LDA-LTC-IC/106 cells was calculated for VENTX2 and the GFP empty vector control as 
described in Material and Methods. p= ns (not significant) 
 
 
Furthermore, the number of colonies generated per LTC-IC did not significantly differ 
between the two arms (175.5 ± 13 CFC/LTC-IC for VENTX2 and 170 ± 18 CFC/LTC-IC for 
the control)(p=ns). CFCs were counted and classified according to the morphology. No major 
differences were observed in the number of GEMM-CFU (VENTX2 26 ± 25.1, MIG 27,33 ± 
25,5) GM-CFC, M-CFU and G-CFU and BFU/CFU-E colonies (Figure 4.14).  
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Figure 4.14. LTC-IC derived CFC. Colonies derived from LTC-IC limiting dilution 
analyses classified according to their morphology. Bars represent mean (±SEM) frequency from two 
independent experiments. p=ns (not singnificant) (n=2).  
4.2.6. Human SCID repopulating cells (SRC) 
Assays to enable the measurement of human repopulating cells have been developed 
using murine xenograft models. Human cells are transplanted intravenously (i.v.) into sub-
lethally irradiated mice such as the non-obese diabetic/severe combined immunodeficient 
(NOD/SCID) mouse. Six to nine weeks later, the percentage of engrafted human cells CD45+ 
in the bone marrow is assessed by flow cytometry. The cell responsible for initiating 
engraftment in the NOD/SCID mouse is termed the SCID-Repopulating Cell (SRC), and 
occurs at low frequencies in the order of one in 9.3x 105 mononuclear cord blood cells. 
Engraftment with human cells was first assessed by FACS analysis of bone marrow cells. 5/5 
mice transplanted with VENTX2 and 9/9 mice transplanted with GFP control transduced cord 
blood cells showed lympho-myeloid engraftment over a period of 9 weeks, indicating that 
sufficient transduced long-term repopulating stem cells have been transplanted. In both arms 
the ratio of lympho-myeloid engraftment was 3 for VENTX2 and 5 for GFP transplanted 
animals. 
To test the impact of VENTX2 on hematopoietic differentiation in vivo, lymphoid 
(CD19+), myeloid (CD15/CD33+), erythroid (Glycophorin A/CD36+) and megakaryocytic 
(CD41+) engraftment was analyzed.  
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VENTX2 induced a 2,9 fold increase in the proportion of granulocytic cells (CD15+ 
mature myeloid cells) within the GFP-positive compartment (n=7) compared to the control 
(n=9) (6.4 ± 1,5 % vs. 2,2 ± 0,5 %, respectively; p<0,01) (Figure 4.15).  
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Figure 4.15. Engraftment of mature human cells. Percent of CD15+ cells within the 
transduced compartment of VENTX2 and GFP mice. p>0.01.  
 
In addition, constitutive expression of VENTX2 in human cord blood cells induced an 
8-fold decrease in the total number of CD34+CD38+ transduced cells (VENTX2 3,5 x 105 (± 
1,8 x 105 CD34+CD38+ in GFP, GFP 3 x 106 ± 1,1 x 106 CD34+CD38+ cells in GFP, p<0,05). 
In contrast, the number of CD38+ cells within the transduced compartment was significantly 
increased by 7 fold, when cord blood cells were transduced with VENTX2 as compared to the 
GFP control: VENTX2 3x107 ± 1x107 CD38+ cells in GFP vs. 1,4 x 106 ± 1,1 x 106 GFP 
control cells, p<0.02.  
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Figure 4.16. Number of CD38 positive cells in NOD-SCID mice. After six weeks NOD-
SCID mice were sacrificed and the number of human CD38 positive cell was determined. 
*p<0.02 
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4.3. SU5614 as a stem cell therapeutic agent  
4.3.1. Cytogenetic profile, classification and characterization of patient 
samples 
To test, whether the protein tyrosine kinase inhibitor (PTKI) SU5614 targets leukemic 
stem cells and spares their normal counterparts, we first analyzed the toxicity profile on 
leukemic cells of patients with acute myeloid leukemia (AML). For this purpose, we used in 
vitro assays representing different stages of hematopoietic development.  
Three groups of patient samples (n=4 per group) were analyzed with non-mutated 
wild-type FLT3 (WT) receptor, with internal tandem duplication FLT3 (ITD) also called 
length mutations (LM) as well as point mutations in the second tyrosine kinase domain at 
codons 835, 836, 841 or 842 (TDK) (Table 4.1). Acute myeloid leukemia was confirmed by 
cytogenetic analysis performed on bone marrow of patients at initial diagnosis. Classification 
and diagnosis of AML patients were based on the criteria of the French-American-British 
(FAB) group. Patient samples were screened by flow cytometry for the presence of the cell 
surface molecules CD117 (c-KIT) and CD135 (FLT3 receptor). Interestingly, FACS analysis 
revealed a high expression of c-KIT (CD117) in 9 of 12 patients. AML was confirmed by the 
percentage of blasts in the bone marrow (BM) and white blood cells (WBC). All data are 
summarized in the table 4.1. 
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Table 4.1. Patient Characteristics. Patient samples were divided into three different groups 
based on the mutations of the FLT3 receptor. The standard methods for establishing the diagnosis of 
acute leukemias are cytomorphology and cytochemistry in combination with immunophenotyping. For 
this purpose leukemic cells were stained for CD117 (c-KIT) antigens and CD135 (FLT3 receptor). 
FAB = French-American-British group; WBC: white blood cell; BM: bone marrow; PB = peripheral 
blood; WT = wild-type; ITD = internal tandem duplication; D835H = point mutation at codon 835. 
4.3.2. Preparation of cells used for toxicological studies with SU5614 
1x 106 AML bone marrow cells from patient samples were pre-incubated for 24 hours 
with or without (control) 10 µM SU5614 and 50 ng/ml of granulocyte colony-stimulating 
Patient Cytogenetics Age FAB WBC 
(x109/ml) 
% blasts in 
BM or PB 
FLT3 
status 
% of 
CD117+ 
% of 
CD135+ 
1 46,XX, Nras+ 68 M1 284 95 WT 33 80 
2 47,XX,I(21),+i(21), 
c-KIT-, Nras- 
67 M2 41 60 WT 41 10 
3 46,XY, c-KIT-, 
Nras- 
46 M4 105 90 WT 32 87 
4 47,XY,+13 
48,XY,+13,+13,c-
KIT- 
71 M1 160 90 WT 64 96 
5 46,XY, c-KIT-, 
MLL dupl- 
47 M1 66,4  ITD 48 40 
6 46,XX, Nras- 55 M4 8,2 90 ITD 23 11 
7 46,XX, c-KIT- 73 M5b 206 90 ITD 2 51 
8 46,XX,t(11;16),c-
KIT-, Nras- 
42 M4 75 90 ITD 10 12 
9 47,XX,+14, c-KIT-
, Nras- 
68 M5a 94 95 D835H 8 93 
10 46,XX, c-KIT-, 
Nras- 
85 M5b 268 95 D835H 15 45 
11 46,XY, c-KIT-, 
Nras-  
48 M2 9 80 Del835 8 3 
12 46,XX, c-KIT-, 
Nras- 
38 M4 10,6 90 D835Y/ITD 37 54 
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factor. It was earlier reported by Spiekermann et al (2003) that the inhibitor induces apoptosis 
at a concentration of 10 µM in transduced myeloid leukemic cell lines 148. After 24 hours, 
cells pre-incubated in liquid culture with and without (control) SU5614 were removed, 
washed and the viability was measured by trypan blue.  
We observed that 1 out of 4 (1/4) patient samples with non-mutated FLT3 (WT), 1/4 
patient samples with ITD, and 2/4 patient samples with TKD (p<0.05) responded with a 
greater than 50 % reduction of leukemic cell number (Table 4.2). However, equal fractions of 
cells pre-incubated with or without (control) SU5614 recovered from cultures, were assayed 
without regard to changes in the cell number.  
 
Figure 4.2. Toxicity of SU5614 after 24 hours pre-incubation. Adherent and non adherent 
cells were harvested after 24 hours. The reduction of living cells between the control arm vs. SU5614 
arm was calculated starting at day 0 and after 24 hours.*Reduction of cell number  compare to the 
control after 24hrs pre-incubation with the inhibitor. 
Patient Cytogenetics % of Blasts in 
Bone Marrow 
(BM) 
FLT3 
status 
% of  
CD117+ 
% of  
CD135+ 
% Toxicity of 
SU5614 after 24 
hrs  
pre-incubation* 
1 46,XX, Nras+ 95 WT 33 80 4 
2 47,XX,I(21),+i(21), c-
KIT-, Nras- 
60 WT 41 10 0 
3 46,XY, c-KIT-, Nras- 90 WT 32 87 9 
4 47,XY,+13 48,XY,+13, 
+13, c-KIT- 
90 WT 64 96 54 
5 46,XY, c-KIT-, MLL 
dupl- 
90 ITD 48 40 39 
6 46,XX, Nras- 90 ITD 23 11 20 
7 46,XX, c-KIT- 90 ITD 2 51 74 
8 46,XX,t(11;16), c-KIT-, 
Nras- 
90 ITD 10 12 0 
9 47,XX,+14, c-KIT-, 
Nras- 
95 D835H 8 93 17 
10 46,XX, c-KIT-, Nras- 96 D835H 15 45 13 
11 46,XY, c-KIT-, Nras-  80 Del835 8 3 83 
12 46,XX, c-KIT-, Nras- 90 D835Y/ITD 37 54 73 
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 4.3.3. Toxicity of SU5614 on clonogenic progenitors tested with the 
Clonogenic forming cells (CFC) assay 
After 24 hours pre-incubation with or without (control) 10 µM of SU5614, 1 to 2x 105 
patient cells were plated in methylcellulose and CFC assays were performed. Colonies were 
scored after 14 days for the presence of clusters (4 to 20 cells) and colonies (more than 20 
cells). The toxicity profile of SU5614 was analyzed on the level of clonogenic progenitors 
(CFC). 2/4 patient samples with WT, 3/3 patient samples with ITD (p<0.004) and 2/2 patient 
samples with TKD responded to therapy with an up to 100 % reduction in the number of 
leukemic clonogenic progenitors as compared to the untreated AML cells. The percentage of 
killing (toxicity) of SU5614 on AML cells for each different cytogenetic group is calculated 
in comparison to the cells pre-incubated without SU5614 (control). It was not possible to 
detect colony growth in some methylcellulose dishes (Table 4.3). The response of leukemic 
CFC to SU5614 could not be predicted from the expression level of FLT3 on the bulk 
leukemic population as determined by the percentage of CD135 positive cells (Table 4.3). 
Response to SU5614 was also not correlated with the presence of activating mutations or 
surface expression of c-KIT, an RTK receptor also targeted by the SU5614 compound. 
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Table 4.3. Toxicity of SU5614 on clonogenic progenitor cells. The effect of SU5614 on 
leukemic clonogenic progenitor cells was analyzed in the CFC assay with or without SU5614. 
Colonies were scored after two weeks.* % toxicity of SU5614 on AML progenitors CFC is calculated 
in numbers of outgrowing colonies in the untreated arm (control) vs. SU5614 treated AML cells.  
4.3.4. Toxicity of SU5614 on Long Term-Initiating Cells (LTC-IC) and 
on Suspension Culture-Initiating Cells (SC-IC) 
AML patient sample cells previously pre-incubated with or without (control) 10 µM 
SU5614 were maintained sex weeks in Long-Term Culture-Initiating Cell (LTC-IC) assays. 
Half-medium change was performed every week as described in chapter 2.12 (Material and 
Methods). After six weeks cells were harvested and assessed for their AML-CFC assay. 
On the level of more immature hematopoietic stem cell candidates, LTC-IC assays 
revealed a response of more than 50 % cell killing in 3/4 (p<0.03) patient samples with WT, 
3/4 (p<0.001) patient samples with ITD and 2/4 patient samples with TDK.  
Furthermore, to the toxicity of SU5614 on the level of long term initiating  cells, cells 
after pre-incubation with and without (control) 10 µM SU5614 inhibitor were detected by 
Suspension Culture Initiating Cell (SC-IC). On the level of long term initiating cells 2/4 
Patient Cytogenetics % of 
CD117+ 
% of 
CD135+ 
FLT3 
status 
* % Toxicity of 
SU5614 on CFC 
1 46,XX, Nras+ 33 80 WT 0 
2 47,XX,I(21),+i(21),  
c-KIT-, Nras- 
41 10 WT 0 
3 46,XY, c-KIT-, Nras- 32 87 WT 93 
4 47,XY,+13 48,XY,+13, 
+13, c-KIT- 
64 96 WT 26 
5 46,XY, c-KIT-, MLL dupl- 48 40 ITD 98 
6 46,XX, Nras- 23 11 ITD 77 
7 46,XX, c-KIT- 2 51 ITD 77 
8 46,XX,t(11;16), c-KIT-, 
Nras- 
10 12 ITD n.g 
9 47,XX,+14,c-KIT-, Nras- 8 93 D835H 32 
10 46,XX, c-KIT-, Nras- 15 45 D835H 100 
11 46,XY, c-KIT-, Nras-  8 3 Del835 n.g 
12 46,XX, c-KIT-, Nras- 37 54 D835Y/ITD n.g 
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patient samples with ITD, and 4/4 patient samples with WT responded to the therapy with 
SU5614. Only in one sample with TDK mutations, SU5614 reduced leukemic HSC. For some 
samples we could not detect any growth in the control arm and thereby the samples were not 
considered (n.g.) (Table 4.4).  
 
Table 4.4. Toxicity of SU5614 on Long Term Initiating Cells (LTC-IC) and Suspencion culture-
initiating cells (SC-IC). After six weeks in LTC-IC and SC-IC assay cells were plated in 
methylcellulose. After two weeks the methylcellulose dishes were scored, colonies were counted and 
toxicity was calculated as described in Material and Methods. In some control arms no growth was 
detected (n.g). For this reason it was not possible to calculate the percentage of toxicity of the 
compound for five samples analyzed with the SC-IC assay.  
4.3.5. Toxicity of SU5614 on CFC, LTC-IC as well as on SC-IC in 
normal bone marrow cells 
As the inhibitor eliminates leukemic HSC from AML patient samples with non-
mutated FLT3 we were further interested to analyze its effect on hematopoietic stem cell 
candidates from healthy donors. As a control CD34+ bone marrow stem cells from healthy 
donors (NBM) were incubated with 1 µM and 10 µM of SU5614 and toxicity was tested for 
Patient Cytogenetics FAB FLT3 
status 
% kill of 
LTC-IC 
% of kill of 
SC-IC 
1 46,XX, Nras+ M1 WT 100 100 
2 47,XX,I(21),+i(21),c-KIT-, 
Nras- 
M2 WT 100 69 
3 46,XY, c-KIT-, Nras- M4 WT 25 100 
4 47,XY,+13 48,XY,+13,+13, c-
KIT 
M1 WT 59 89 
5 46,XY, c-KIT-, MLL dupl- M1 ITD 100 100 
6 46,XX, Nras- M4 ITD 100 n.g 
7 46,XX, c-KIT- M5b ITD 0 n.g 
8 46,XX,t(11;16), c-KIT-, Nras- M4 ITD 
 
69 100 
9 47,XX,+14, c-KIT-, Nras- M5a D835H 0 n.g 
10 46,XX, c-KIT-, Nras- M5b D835H 100 100 
11 46,XY, c-KIT-, Nras-  M2 Del835 83 n.g 
12 46,XX, c-KIT-, Nras- M4 D835Y/ITD 14 n.g 
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the different stages in the hematopoietic progenitor hierarchy. Depending on the dose of 
SU5614 we observed a considerable toxicity on the level of clonogenic progenitor cells on 
normal bone marrow from healthy donors. At the concentration of 10 µM SU5614 had 
considerable toxicity, killing with a mean of 67.5 % (s.d ± 30.6) of the total of CFC and 40.5 
% (s.d ± 32.4) when 1 µM of the drug were applied (n=3) (Figure 4.17). 
 
Figure 4.17. Toxicity of SU5614 on normal bone marrow (NBM) cells. Normal bone 
marrow cells were incubated with 1 µM and 10 µM of the RTKI SU5614. After pre-incubation with 
the inhibitor, the drug was washed away and cells were put in methylcellulose. After two weeks, the 
growth of colonies was scored in both arms and the toxicity was determined.  
 
 
In addition, we performed assays to detect the toxicity on the in vitro equivalent of 
normal long-term repopulating stem cells, the LTC-IC and on suspension culture initiating 
cells, SC-IC, of human BM cells. Based on our previous results of SU5614 on leukemic cells, 
we pre-incubated normal bone marrow cells with 10 µM of the inhibitor. Surprisingly, we 
observed that the compound efficiently eliminated human LTC-IC (78 - 86 %) analyzed in the 
long term initiating cell assay (n=2). In addition, the SC-IC assay (n=1) showed a reduction of 
100 % on the suspension cells analyzed after 24 hours pre-incubation (Table 4.5). 
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% CD34+ enriched 
BM (<98%) 
 
 
Arms  
 
 
 
No. of LTC-IC derived 
colonies /104 CD34+ 
cells 
% of cells reduction 
 
 
 
NBM1 Control 187  
 SU5614 26 86 
NBM2 Control 259  
 SU5614 56 78 
 
 
   
% CD34+ enriched 
BM (<98%) 
Arms  
 
No. of SC-IC derived 
colonies /104 CD34+ 
cells 
% of cells reduction 
 
NBM1 Control   
 SU5614 3202 100 
 
Table 4.5 Toxicity of SU5614 on normal bone marrow (NBM) cells. Toxicity of SU5614 
was tested on normal bone marrow cells from healthy donors. Assays to detect normal LTC-IC human 
BM cells and normal SC-IC human BM cells were performed plating the cells after six weeks of long 
term liquid culture and short term liquid culture in methylcellulose. Colonies were scored after two 
weeks. 
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5. DISCUSSION 
5.1. The hematopoietic PBX interacting protein HPIP plays 
a role in early stem cell development  
The identification of novel proteins which regulate human stem cell and early 
progenitor cell fate decisions is a major goal in experimental and clinical hematology. The 
molecular network controlling stem cell fate decisions is largely unknown, multiple studies 
have attributed a key role in this developmental process to transcription factors. Homeobox 
(HOX) genes are characterized as ‘master genes’ of early hematopoietic development. HOX 
genes are highly expressed in early hematopoietic stem and progenitor cells and down-
regulated during differentiation. In parallel, Hox genes are implicated directly in human 
leukemia, at the level of Hox-cofactors (MEIS1 and PBX1) and HOX gene upstream 
regulators (MLL, CDX2) (Lawrence, Sauvageau et al. 1996; Buske and Humphries 2000). 
Among these HOX proteins, the significance of the interaction with Pbx and Meis partners for 
oncogenic function has been addressed for HOXB3, HOXB4, HOXB7, and HOXA9, as well as 
for the fusion genes NUP98-HOXA9 and NUP98-HOXD13 149-152. The interaction between 
PBX1 and HOX genes is also important for normal hematopoietic differentiation. Buske et al. 
(2002) could show that the constitutive expression of HOXB4 in human hematopoietic 
progenitor cells leads to an amplification of normal HSC with a normal differentiation 
program 153. By knocking down the endogenous expression of PBX1 (PBX1,K.D.) in HOXB4 
overexpressing cells, Krosel et al. (2003) were able to generate HSCs that are >20-times more 
competitive in repopulating assays than those that overexpress HOXB4 and PBX1 154. They 
also showed that the in vivo expansion of HOXB4-PBX1(K.D.) expressing HSCs regenerated 
normal stem cell pools and did not lead to HSC levels above those detected in unmanipulated 
mice 154. Together, these findings underline the significant role of PBX1 together with HOX 
genes for normal HSC development and for leukemogenesis. Therefore, genes that might 
interact with PBX1 are of particular interest for normal as well as leukemic hematopoiesis.  
 Recently, the novel human protein HPIP, which interacts with PBX1 and is highly 
expressed in human CD34+ progenitor cells, has been characterized 30,31. HPIP can bind all 
members of the PBX family. Interestingly, HPIP seems to inhibit the transcriptional 
activation of the E2A-PBX1 fusion protein 30,31. The E2A/PBX1 fusion gene is the result of a 
reciprocal translocation t(1;19)(q23;p13). This translocation occurs only rarely in adults with 
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ALL but accounts for 25–30 % of pediatric ALL cases with a pre-B immunophenotype and 
has been associated with a relatively poor outcome with traditional combination 
chemotherapy 30,31,155. We analyzed the role of HPIP in human hematopoiesis by retroviral 
gene transfer into human cord blood cells.  
We could demonstrate that the constitutive expression of HPIP in human 
hematopoietic stem cells has an impact on self renewal and differentiation. It induces a 
significant increase in the frequency of clonogenic (CFC) (figure 4.2) as well as long-term 
culture initiating cells (LTC-IC), the in vitro equivalent of hematopoietic stem cells (Table 
4.3). This effect was comparable with the stem cell amplificatory effect of HOXB4 in the 
human system as recently shown by Buske et al. (2002) in vitro and in vivo in the NOD/SCID 
mouse model 153. Notably, besides its effect on maintenance of primitive hematopoietic 
progenitor cells, constitutive expression of HPIP did not block terminal hematopoietic 
differentiation. In none of the animals tested and in none of the in vitro assay systems we 
could observe a leukemic transformation. Interstingly, microarray data could prove high level 
of HPIP expression in bone marrow of AML patients, but further studies have to show the 
functional relevance of these findings. Our data characterize HPIP as a novel regulatory 
protein of early human hematopoietic development 
5.2. The Vent gene family member VENTX2 plays a role in 
myeloid development 
As we could determine the stem cell amplificatory effect of HPIP, we were further 
interested to identify new potential stem cell regulatory proteins. Recent data indicate that a 
variety of regulatory molecules, active in early development, may also play a role in the 
maintenance of hematopoietic stem cells with repopulating activity. One such regulatory 
protein is the VENTX2 protein which belongs to family of Xvent genes. The X. laevis Vent 
(Xvent) genes constitute a multigene family encoding homeodomain (HD) proteins with very 
similar DNA-binding domains 156. Xvent genes can be divided into two subfamilies on the 
basis of sequence homology outside of the HD. Each subfamily member contains almost 
identical HD sequences and has more than 80 % identity over the remainder of the protein 
sequence. Xvent1, Xvent1B, and PV1 156,157 are members of the Xvent1 HD subfamily and 
contain little sequence homology outside of the HD to the Xvent2 subfamily members 
Xvent2, Xvent2B, Vox1 (also known as Xbr1b), Vox15, Xom, and Xbr1a 156-158. Members of 
the Xvent class of HB genes are essential for the patterning of ventral mesoderm and 
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hematopoietic development in the X. laevis embryo 33. Ectopic expression of all Xvent genes 
leads to ventralization of X. laevis embryos156,159. The recently described zebrafish ventral 
homeobox (vox) and ventral expressed homeobox (vent) genes show a high degree of 
sequence homology to the Xvent family within the HD and have similar expression patterns. 
These genes are also potent ventralizing factors in both zebrafish and X. laevis embryos. 
Many HB sequences have been isolated from an immature population of human 
hematopoietic progenitor cells 160. The VENTX2 HD had 65 % identity to the HD in X. laevis 
Xvent2B 156. VENTX2 is to our knowledge the first member of the Vent gene family of 
diverged HB genes described in mammals. The Vent-like homeobox genes were shown to be 
involved in early developmental processes and the ventralizing activity of Vent downstream 
of the morphogen BMP4, which has potent ventralizing activity and is involved in specifying 
the dorsal-ventral axis during early embryogenesis 161,162. 
 Therefore the aim of the project was to evaluate the expression of VENTX2 in 
different lineages of the hematopoietic compartment and to test the function of the human 
homologue VENTX2 in hematopoietic development. 
To examine the impact of VENTX2 expression on hematopoietic progenitors we first 
tested the clonogenic potential of CD34+VENTX2+ transduced cord blood cells. At the level of 
clonogenic progenitors VENTX2 induced myeloid and blocked erythroid differentiation with a 
significant 1.7 fold increase in the number of G-CFU and a 4,25 fold decrease in the number 
of erythroid colonies without any change of the total number of colonies produced (Figure 
4.10). In addition, we did not only observe a shift in the differentiation program towards the 
myeloid lineage, but also an increased proliferative activity of clonogenic progentitors when 
colonies from primary methylcellulose were replated (Figure 4.11). 
To test, whether the constitutive expression of VENTX2 would also have an impact on 
the most primitive hematopoietic progenitors, we performed long-term culture assays and 
transplanted NOD/SCID mice. We could not detect a change of the frequency of LTC-IC’s 
between VENTX2 transduced cells and the control arm (Figure 4.13). Furthermore, the 
number of colonies generated per LTC-IC did not significantly differ between the two arms. 
Similarly, the frequency of NOD/SCID repopulating cells was not changed, when cord blood 
cells transduced with VENTX2 were transplanted and compared to the control.  
However, when NOD/SCID mice transplanted with human cord blood cells 
constitutively expressing VENTX2 were analyzed over time, we saw a decrease in the number 
of CD34+CD38- primitive cells as compared to those animals that received control cells. In 
contrast, we detected a 7 fold increase in the absolute number of CD38+ cells and a 3 fold 
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increase in the number of CD15+ myeloid cells indicating again an impact of VENTX2 on 
more mature hematopoietic myeloid progenitor cells (Figure 4.15). 
Preliminary RT-PCRs data could detect VENTX2 expression in CD15, CD19 and 
CD33 cells highly purified by FACS from umbilical cord blood Expression of VENTX2 was 
detected in B cells - as well as differentiated myeloid cells indicating that VENTX2 is 
expressed in multiple hematopoietic lineages. In addition, VENTX2 expression was detected 
in CD34+, CD38+ and CD34-CD38+ cord blood cells. Furthermore, we did not found VENTX2 
expression within the compartment of early CD34+CD38- cord blood cells. (data not shown). 
In summary, we could identify VENTX2 as a new hematopoietic regulatory gene that mainly 
plays a role in more mature myeloid hematopoietic development. Using our model systems, 
we could not detect any malignant transformation caused by the constitutive expression of 
VENTX2.  
5.3. SU5614 as a stem cells therapeutic agent 
It has been shown that acute myeloid leukemia results from the malignant 
transformation of an early hematopoietic progenitor cell. Primitive normal and leukemic 
hematopoietic progenitors share many cell surface phenotypic characteristics such as the 
expression of CD34 with the lack of CD38 and other lineage markers. However, some 
differences between these cells have been identified that allow them to be separated by flow 
cytometry (Feuring-Buske et al Blood). It seems possible that such unique characteristics of 
AML progenitors could be targeted for therapeutic purposes. The use of agents such as kinase 
inhibitors in hematological malignancies offers the exciting possibility of treating patients 
based on the molecular pathology of diseases. Acute myeloid leukemia (AML) is a malignant 
disorder of hematopoietic cells characterized by an accumulation of highly proliferative blasts 
blocked in differentiation at various stages 40. It is known that mutations in the receptor 
tyrosine kinase FLT3 occur in 30% of AML patients and in a subset of acute lymphoblastic 
leukemia 1,163. Activating mutations in FLT3 are most frequently internal tandem duplications 
(ITD), also called length mutation (LM), within the juxtamembrane coding sequence of the 
receptor occurring in 20 - 27 % of patients with AML 97,98 and a point mutation at residue 835 
(Asp835) within the second kinase domain occurring in about 7 % of patients with AML 
101,102. Due to this high frequency of mutations FLT3 is the most commonly mutated gene in 
AML. ITD and point mutation spontaneously activate tyrosine kinase activity and induce 
factor independent proliferation of hematopoietic cell lines. Recently, a number of small 
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molecule protein tyrosine kinase (PTK) inhibitors targeting constitutively activated FLT3 
were developed. Inhibition of FLT3 kinase activity using small molecule inhibitors induces 
apoptosis in cell lines and prolongs survival of mice expressing mutant FLT3 in their bone 
marrow cells 136,164. In our study the correlation between drug sensitivity in vitro and the 
mutation status of the FLT3 receptor gene was evaluated on blast cells from patient with 
AML. We used SU5614, a member of the rapidly growing family of PTKI, an indolinone 
compound that inhibits the tyrosine kinase activity of the FLT3 receptor. It was predicted to 
target leukemic stem and progenitor cells while sparing their normal counterparts.  
To test, whether these characteristics are met by SU5614, we first analyzed the anti-
leukemic activity of the compound on the leukemic cell population of patients with AML. 
Three groups of patients (n=4 per group) were analyzed with non-mutated wild-type FLT3 
(WT), internal tandem duplication ITD, as well as point mutations in the FLT3 kinase domain 
(D835H, D835H, D835Y, del835). After 24 hours of pre-incubation with the inhibitor in 
liquid culture, patient samples with non-mutated FLT3 with ITD and with point mutations 
responded with a greater than 50 % reduction of leukemic cell number (Table 4.3). On the 
level of clonogenic progenitors 2/4 patient samples with WT, 3/3 with ITD and 2/2 patient 
samples with point mutations responded to therapy with an up to 100 % reduction of the 
number of leukemic clonogenic progenitors (Table 4.3). 
Importantly, on the level of leukemic stem cells, the compound achieved a > 50 % cell 
death in 3/4 and 4/4 patient samples with WT FLT3, as determined by LTC-IC assay and SC-
IC assay, respectively (Table 4.4). In the group of ITD positive 3/4 and 2/2 patient samples 
showed a more than 50 % cell kill in the LTC-IC and SC-IC assay, respectively. For samples 
with the D835 mutations SU5614 reduced leukemic stem cells by more than 50 % in 2/4 
samples as determined by the LTC-IC assay (Table 4.4). These data indicate that the RTK 
inhibitor is highly active in the majority of cases in reducing the size of the leukemic bulk 
population, the number of leukemic clonogenic progenitors and most importantly, the number 
of leukemic stem cells. However, sensitivity to SU5614 was very heterogeneous, ranging 
from total eradication of leukemic cells to non-response. Furthermore, the response of both 
clonogenic progenitor cells as well as leukemic stem cells to SU5614 could not be predicted 
from the expression level of FLT3 on the bulk leukemic population as determined by the 
percentage of CD135 positive cells (Table 4.1). This may reflect different expression profiles 
for FLT3 functionally distinct progenitor populations or for other stem cell-relevant tyrosine 
kinase that are also targeted by the inhibitor. Response to SU5614 RTKI did also not correlate 
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with the presence of activating mutations or surface expression of c-KIT, an RTK also 
targeted by the compound SU5614.  
The RTK family includes KIT (CD117; c-KIT, stem cell factor), the receptors for 
macrophage colony-stimulating factor (M-CSF) and platelet-derived growth factor (PDGF), 
which all show a high sequence homology. Because of this high homology SU5614 is not 
only FLT3 specific but also inhibits c-KIT and VEGFR 148. None of the patient samples 
analyzed showed an activating mutation of c-KIT (Table 4.2). However, FACS analysis 
revealed a high expression of c-KIT (CD117) on 9/12 patients. The combined inhibitory 
effect of SU5614 on FLT3 as well as c-KIT might be responsible for the observed response. 
Furthermore, CD34+ bone marrow stem cells from healthy donors were incubated with and 
without (control) SU5614 and toxicity was tested for the different stages in the hematopoietic 
progenitor hierarchy. On the level of normal clonogenic progenitors SU5614 had considerable 
toxicity also using different concentration of the drug. The cell killing leads to a mean 
reduction of 40.5 % (s.d ± 30.6) of the cells at 1 µM and 67.5 % (s.d ± 32.4) at 10 µM (Figure 
4.17). In addition, the compound efficiently eliminated normal human stem cells analyzed in 
the LTC-IC assay (n=2) or the SC-IC assay (n=1) at 10 µM with a range between 78 – 100 % 
after 24 hours incubation (Table 4.6). Mice deficient for two RTKs, such as c-kit and flk2 
demonstrate a more severe phenotype characterized by large overall decreases in 
hematopoietic cell numbers, further reductions in the relative frequencies of lymphoid 
progenitors, and a postnatal lethality. These observations suggest a role of flk2 in multipotent 
stem cells and lymphoid differentiation 165. Our data indicate that SU5614 is a potent drug for 
the elimination of leukemic stem cell candidates from patients with ITD+, D835+ AML as 
well as those with non-mutated FTL3. However, SU5614, targeting FLT3, VEGFR-2 and Kit, 
is not sparing the normal stem cell compartment. These data suggest that PTKI’s with activity 
against different receptor tyrosine kinases have a considerable inhibitory effect on normal 
human progenitor cells which might have clinical relevance in the treatment of patients with 
AML or MDS with compromised normal hematopoietic capacity. 
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6. SUMMARY 
The hallmark of hematopoietic stem cells (HSC) is their ability of self-renewal and 
differentiation into multiple hematopoietic cell lineages. Although the molecular network 
controlling stem cell fate decisions is largely unknown, multiple studies have attributed a key 
role to transcription factors in this developmental process. In this context the family of 
homeobox genes was characterized as ‘master genes’ of this early hematopoietic 
development. The identification of new genes involved in normal and leukemic hematopoiesis 
and the development of therapies against deregulated processes in hematopoiesis are the 
major goals in experimental and clinical hematology. . The identification of new genes 
involved in normal and leukemic hematopoiesis and the development of therapies against 
deregulated processes in hematopoiesis are the major goals in experimental and clinical 
hematology. Therefore, the focus of this thesis was the characterization of two novel putative 
regulatory proteins of early human hematopoiesis, the hematopoietic PBX-interacting protein 
(HPIP) and the human Vent-like Homeobox gene (VENTX2) and to investigate to the activity 
of the FLT3 protein kinase inhibitor SU5614 on leukemic blast from AML patient samples. 
Using complex in vitro assays we analyzed the impact of constitutive expression of 
HPIP and VENTX2 on stem cell and early human hematopoietic development. To detect 
clonal progenitor cells primary and secondary colony-forming-unit (CFC) assays were 
performed. In addition the in vitro equivalent of HSC long-term culture initiating cells were  
detected with the (LTC-IC) assay. 
We were able to show that the constitutive expression of HPIP can rapidly lead to 
increased numbers of cells detected on the level of committed clonogenic progenitor cells and 
LTC-ICs. In addition, the production of CFC per LTC-IC is markedly enhanced when cord 
blood (CB) cells are transduced with HPIP as compared to the control. Notably, besides its 
effect on maintenance of primitive hematopoietic progenitor cells, constitutive expression of 
HPIP did not block terminal hematopoietic differentiation. Additional we could show that the 
constitutive expression of HPIP leads to an increase of myeloid cells in transplanted 
NOD/SCID mice. These data characterize HPIP as a novel regulator of the early human 
hematopoietic stem cell, demonstrating that its constitutive expression has a notable impact on 
self renewal and differentiation of human hematopoietic stem cells. 
In vitro and in vivo analyses shed light on the understanding to the function of the 
homeobox gene VENTX2. On the level of the most primitive hematopoietic progenitors we 
could not observe a significant increase in the frequency of HSCs. Furthermore, the number 
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of colonies generated per LTC-IC did not significantly differ between the VENTX2 arm and 
the control arm. A strong effect was obtained on the level of clonogenic progenitor cells. 
VENTX2 increased the production of myeloid cells 1.7-fold in comparison to the control. 
Secondary replating assay confirmed the amplificatory effect of VENTX2 transduced cells in 
the number of secondary G-CFU indicating that VENTX2 promote myeloid lineage 
differentiation. Interestingly, on the level of clonogenic progenitors VENTX2 expression 
resulted in a significantly decreased growth of erythroid colonies by 4.2-fold compared to the 
control suggesting that constitutive expression of VENTX2 may inhibit early erythroid 
differentiation. This inhibition did not occur on the level of primitive hematopoietic cells 
detected by Limiting Dilution LTC-IC assay where VENTX2 increased within a 2.2 fold 
compared to the control. 
 The observation that VENTX2 overexpression drives CD34+ to differentiate into 
myeloid lineage was additional proved by in vivo experiments. In NOD/SCID mice VENTX2 
induced a 3-fold increase in the proportion of CD15+ mature myeloid cells within the GFP-
positive compartment compared to the control. A 7-fold increase was observed in the total of 
CD38+ GFP+ cells in comparison to the MIG mice control (p<0.01). Furthermore, VENTX2 
transduced cells increased the proportion of CD34-CD38+ cells 1.2 fold compared to the 
control suggesting that VENTX2 expands the compartment of more differentiated progenitors 
in vitro  as well as in the NOD/SCID mouse model. This implicates a amplificatory effect of 
the VENTX2 expression on differentiated progenitor cells. All together, these data characterize 
VENTX2 as a novel regulatory protein in human hematopoiesis adding information about the 
role of non-clustered homeobox genes in early blood development. 
In an additional project of this thesis, we tested the specificity of the FLT3 protein 
kinase inhibitor SU5614 on normal and leukemic blasts from patients with acute myeloid 
leukemia. Here we could demonstrate the efficiency of the compound to eliminate the 
leukemic stem cell in AML patient samples with mutated as well as non mutated FLT3 
receptor. However, our data also point to a considerable toxicity on normal HSC, which 
should be taken in account in the management of patients with compromised normal 
hematopoiesis. 
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7. ZUSAMMENFASSUNG 
Das Merkmal hämatopoetischer Stammzellen ist ihre Fähigkeit sich selbst zu erneuern und in 
verschiedene hämatopoetische Zelllinien zu differenzieren. Obwohl das molekulare 
Netzwerk, welches die Entscheidung über das Schicksal der Stammzellen kontrolliert, noch 
größtenteils unbekannt ist, wurden in verschiedenen Studien diversen Transkriptionsfaktoren 
eine Schlüsselrolle in diesem Entwicklungsprozess zugeschrieben. In diesem Zusammenhang 
wurde die Familie der Homeoboxgene als eine Klasse von „Mastergenen“ in der frühen 
Hämatopoese charakterisiert. Das Hauptziel der experimentellen und klinischen Hämatologie 
ist die Identifizierung neuer Gene, welche eine entscheidene Rolle in der normalen und 
leukemischen Hämatopoese spielen, sowie die Entwicklung von Therapien gegen deregulierte 
Prozesse in der Hämatopoese.  
 Das Ziel dieser Doktorarbeit war es die Rolle der Gene HPIP (hämatopoetisches 
PBX-interagierendes Protein) und VENTX2 (humanes Vent-ähnliche Homeoboxgen 2) in der 
normalen und leukemischen Hämatopoese zu klären. Des Weiteren wurde die Wirkung des 
spezifischen FLT3 Proteinkinaseinhibitors SU5614 an leukämischen Blasten von AML 
Patientenproben untersucht.  
Mit Hilfe von anspruchsvollen in vitro Methoden haben wir die einzelnen Stadien der 
Zelldifferenzierung hämatopoetischer Stammzellen in Abhängigkeit der Expression von HPIP 
und VENTX2 analysiert. Zur Detektion von klonalen Vorläuferzellen wurden primäre und 
sekundäre Kolonie-formende Zellassays (CFCs) durchgeführt, die Detektion von in vitro 
Equivalenten hämatopoetischer Stammzellen erfolgte mittels Langzeit-Kultur-initiierenden 
Zellassays (LTC-ICs). Desweiteren wurden in vivo NOD/SCID Mausmodelle etabliert.  
Wir waren in der Lage zu zeigen, dass die konstitutive Expression von HPIP zu einer 
raschen Zunahme an klonalen Vorläuferzellen und LTC-ICs führt. Zusätzlich konnten wir 
belegen, dass nach Transduktion von Nabelschnurblutzellen mit HPIP die Produktion der 
CFCs pro LTC-IC deutlich zunimmt. Es ist bemerkenswert, dass die konstitutive Expression 
von HPIP, neben den Effekten auf die Aufrechterhaltung primitiver hämatopoetischer 
Vorläuferzellen, die terminale hämatopoetische Differenzierung nicht blockiert. Außerdem 
konnten wir zeigen, dass die konstitutive Expression von HPIP zu einer Zunahme an 
myeloiden Zellen in transplantierten NOD/SCID Mäusen führt. Diese Daten charakterisieren 
HPIP als einen neuen Regulator der frühen humanen hämatopoetischen Stammzelle. Seine 
konstitutive Expression in humanen hämatopoetischen Stammzellen hat einen deutlichen 
Einfluss auf die Selbsterneuerung und Differenzierung dieser Zellen. 
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 In vitro und in vivo Untersuchungen im Rahmen dieser Arbeit haben zum Verständnis 
der Funktion des Homeoboxgens VENTX2 beigetragen. Auf dem Level der primitivsten 
hämatopoetischen Vorläuferzellen konnten wir nach Expression von VENTX2 keine 
signifikante Zunahme an hämatopoetischen Stammzellen im Vergleich zur Kontrolle 
erkennen. Außerdem zeigt sich in der Anzahl der generierter LTC-IC nach VENTX2 
Expression kein signifikanter Unterschied im Vergleich zur Kontrolle. Einen deutlichen 
Effekt konnten wir auf dem Level der klonalen Vorläuferzellen beobachten. Die VENTX2 
Expression erhöhte die Produktion myeloider Zellen im Vergleich zur Kontrolle um das 1,7-
fache. Sekundäre Wiederausplattierungs-Experimente bestätigten den amplifizierenden Effekt 
der VENTX2 Expression auf die myeloide Blutzellliniendifferenzierung. Des Weiteren stellten 
wir fest, dass bei CFCs das Wachstum erythroider Kolonien signifikant um das 4,95-fache 
erniedrigt ist, woraus man schließen kann, dass eine konstitutive Expression von VENTX2 
möglicherweise die Differenzierung von erythroiden Vorläuferzellen (BFU-E) inhibitiert. 
Diese Inhibition trat nicht auf dem Level primitiver hämatopoetischen Zelle auf. Die VENTX2 
Expression führte zu einer 2,2 fachen Zunahme von LTC-ICs im Vergleich zur Kontrolle. 
 Die Feststellung, dass die VENTX2 Überexpression Stammzellen zur Differenzierung 
in Richtung der myeloide Blutzelllinie treibt, wurde zusätzlich durch in vivo Experimente 
bestätigt. In NOD/SCID Mäusen induzierte die VENTX2 Überexpression eine dreifache 
Zunahme an reifen, myeloiden CD15+ Zellen innerhalb des GFP-exprimierenden Anteils an 
Blutzellen. Es konnte insgesamt eine siebenfache Zunahme an CD38+ GFP+ Zellen im 
Vergleich zu MIG transformierten Kontrollmäusen festgestellt werden (p<0.01). Des 
Weiteren erhöhen VENTX2 transduzierte Zellen den Anteil an CD34-CD38+ Zellen um das 
1,2-fache im Vergleich zur Kontrolle. Dies lässt vermuten, dass die VENTX2 Expression den 
Anteil an differenzierten Vorläuferzellen sowohl in vitro als auch in dem NOD/SCID-
Mausmodell erhöht. Dies legt einen amplifikatorischen Effekt der VENTX2 Expression in 
differenzierten Vorläuferzellen nahe. Zusammenfassend kann man sagen, dass die Ergebnisse 
dieser Doktorarbeit VENTX2 als ein neues regulatorisches Protein in der humanen 
Hämatopoese charakterisieren und neue Informationen über die Rolle von nicht-geclusterten 
Homeoboxgenen in der frühen Blutzellentwicklung geben. 
In einem weiteren Projekt dieser Doktorarbeit haben wir schließlich den spezifischen 
FLT3 Proteinkinaseinhibitor SU5614 auf normalen und leukemischen Blasten von Patienten 
mit akuter myeloider Leukemie (AML) getestet. Hierbei konnten wir die Effizienz des 
Inhibitors zur Eliminierung leukemischer Stammzellen von AML Patienten, sowohl mit als 
auch ohne mutierten FLT3 Rezeptor, nachweisen. Dennoch muss gesagt werden, dass unsere 
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Daten auf eine nicht unerhebliche Toxizität des Inhibitors auf normale HSC hinweisen, die 
man bei der Behandlung von Patienten mit eingeschränkter normaler Hämatopoese mit 
diesem Inhibitor unbedingt in Betracht ziehen muss.  
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10. ABBREVIATIONS 
 
µL Microliter 
µM Micromola 
ALL Acute lymphoid leukemia 
AML Acute myeloid leukemia 
BFU-E  
BM Bone marrow 
CB Cord blood 
CD Cluster of Differentiation           
CFC Colony forming cell 
CSF Colony stimulating factor 
DMSO Dimethylsulfoxid 
DNA Desoxyribonucleic acid 
EPO Erytropoietin 
FAB French American British 
FACS Fluoresence Activated Cell Sorting 
FISH Flurecence in situ hybridisation 
FLT3 FMS-like tyrosine kinase 3 
G-CSF Granulocite-Colony stimulating factor  
GM-CSF Gramulocite-Macrophage-Colony stimulating factor  
HB Homeobox gene 
HD Homeodomain 
IL interlulukin 
ITD  Internal tandem duplication 
LDA-LTC-IC Limiting dilution assay LTC-IC 
LM Lenght mutation 
LTC-IC Long-term culture-initiating cell 
LTR  Long terminal repeat 
M-CSF Macrophage-Colony stimulating factor  
MIG MSCV-IRES-EGFP 
MNC Mononuclear cell 
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MSCV Murine Stem Cell Virus 
NBM Normal bone marrow 
NOD-SCID mice Non Obese Deficent-Sever Compromise Immuno Deficent Mice 
PB Peripheral blood 
PCR Polymerase Chain Reaction 
PI Propidium iodide 
PTK Phospho tyrosine kinase 
PTK Protein Tyrosine Kinase 
PTKI Protein Tyrosine Kinase Inhibitor 
RNA Ribonucleic acid 
S-CFU-S Spleen-Colony forming unit  
SC-IC Suspension culture- initiating cell 
SEM Standard error of the mean 
t translocation 
TDK Tyrosine kinase domain 
TM Transmembrane domain 
VCM Virus containing medium 
WBC White blood cell 
WT Wild type 
YFP Yellow Fluorescent Protein 
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